# The relationship between controllability, optimal testing resource allocation, and incubation-latent period mismatch as revealed by COVID-19

Jeffery Demers<sup>1,2,\*</sup>, William F. Fagan<sup>2</sup>, Sriya Potluri<sup>2</sup>, and Justin M. Calabrese<sup>1,2,3</sup>

<sup>1</sup>Center for Advanced Systems Understanding (CASUS), Helmholtz-Zentrum Dresden-Rosendorf (HZDR), Görlitz, Germany

<sup>2</sup>Dept. of Biology, University of Maryland, College Park, MD, USA

<sup>3</sup>Dept. of Ecological Modelling, Helmholtz Centre for Environmental Research-UFZ,

Leipzig, Germany

\*Corresponding author; Email: jdemers@umd.edu

#### Abstract

1

The severe shortfall in testing supplies during the initial COVID-19 outbreak and ensu-2 ing struggle to manage the pandemic have affirmed the critical importance of optimal supply-3 constrained resource allocation strategies for controlling novel disease epidemics. To address 4 the challenge of constrained resource optimization for managing diseases with complications 5 like pre- and asymptomatic transmission, we develop an integro partial differential equation 6 compartmental disease model which incorporates realistic latent, incubation, and infectious pe-7 riod distributions along with limited testing supplies for identifying and quarantining infected 8 individuals. Our model overcomes the limitations of typical ordinary differential equation com-9 partmental models by decoupling symptom status from model compartments to allow a more 10 realistic representation of symptom onset and presymptomatic transmission. To analyze the 11 influence of these realistic features on disease controllability, we find optimal strategies for re-12 ducing total infection sizes that allocate limited testing resources between 'clinical' testing, which 13 targets symptomatic individuals, and 'non-clinical' testing, which targets non-symptomatic in-14 dividuals. We apply our model not only to the original, delta, and omicron COVID-19 variants, 15 but also to generically parameterized disease systems with varying mismatches between latent 16 and incubation period distributions, which permit varying degrees of presymptomatic transmis-17 sion or symptom onset before infectiousness. We find that factors that decrease controllability 18 generally call for reduced levels of non-clinical testing in optimal strategies, while the relationship 19 between incubation-latent mismatch, controllability, and optimal strategies is complicated. In 20 particular, though greater degrees of presymptomatic transmission reduce disease controllabil-21 ity, they may increase or decrease the role of non-clinical testing in optimal strategies depending 22 on other disease factors like transmissibility and latent period length. Importantly, our model 23 allows a spectrum of diseases to be compared within a consistent framework such that lessons 24 learned from COVID-19 can be transferred to resource constrained scenarios in future emerging 25 epidemics and analyzed for optimality. 26

Keywords: Testing Quarantine Control, Optimal Resource Allocation, Presymptomatic Trans mission, Latent Period, Incubation Period, Age of Infection

# <sup>29</sup> 1 Introduction

Since its declaration as a global pandemic in March 2020 (1), COVID-19 has caused over 600 30 million cumulative infections and 6 million deaths (2). This loss of life and productivity together 31 with ubiquitous lockdowns and mobility restrictions have resulted in devastating socioeconomic 32 consequences worldwide (3, 4). The particularly severe costs of lockdowns underscore the need for 33 effective large scale test-trace-quarantine programs to combat emerging disease epidemics and save 34 lives while keeping society open and functioning. Unfortunately, for an epidemic caused by a novel 35 pathogen, testing supplies and health care infrastructure may be inadequate to meet demand as 36 health agencies struggle to implement new techniques and technologies at population-wide scales. 37 During the initial phases of the COVID-19 pandemic, for example, testing capacities fell well-short 38 of the levels required to monitor populations and test all suspected cases, while processing delays 39 limited the usefulness of the tests that were actually available (5, 6). Even now, 3 years after the 40 emergence of COVID-19, testing supplies have repeatedly struggled to meet the demand during 41 case surges associated with new COVID variants (6). 42

When COVID resources have fallen short of demand, experts and health agencies have rec-43 ommended the prioritization of testing supplies to the most severely symptomatic and vulnerable 44 patients typically found in clinical health care settings, rather than to non-clinical cases associated 45 with mildly or asymptomatic individuals and population monitoring programs (6, 7, 8). This strat-46 egy seeks to maximize the utility of the few resources available by limiting the amount 'wasted' 47 on individuals who are not infected, but in the process excludes the possibility of slowing disease 48 spread by identifying and quarantining non-symptomatic infected individuals (9). Achieving an 49 ideal balance between clinical and non-clinical resource allocation is especially pertinent for a dis-50 ease like COVID-19, where undetected presymptomatic transmission caused by mismatched latent 51 and incubation periods (10, 11) as well as potentially large numbers of undetected totally asymp-52 tomatic spreaders (12, 13, 14, 15) present significant barriers to controllability. 53

Given the complexity of real-world disease dynamics with features like symptom-based testing and pre- and asymptomatic transmission, simplified compartmental mathematical models can provide powerful tools for analyzing and optimizing control strategies in the face of resource limitations. However, overly simplistic models can yield erroneous conclusions regarding real-world

control strategies, so one must carefully balance model simplicity against the complex realistic 58 elements most relevant to the problem at hand. Conventional compartmental COVID-19 control 59 models are typically based on systems of ordinary differential equations (ODE's) (16, 17, 18, 19, 20, 60 21, 22, 23, 24, 25). While ODE disease models provide a level of mathematical tractability, they 61 necessitate the coupling of symptom status to specific model compartments, and this structural 62 constraint can result in unnatural or unrealistic representations of symptom onset and presym-63 tomatic transmission with potential unintended consequences on model behavior and real-world 64 interpretations. This limitation is especially problematic when modeling controls like clinical and 65 non-clinical testing strategies that are directly tied to symptom status. 66

ODE models for COVID-19 have generally addressed symptom onset and presymptomatic trans-67 mission by one of two broad schemes, both of which have their own drawbacks. One class of models 68 simply ignores the potential for presymptomatic transmission by having infected individuals tran-69 sition from an exposed non-symptomatic non-infectious compartment to an infectious symptomatic 70 compartment, often with an additional infection channel comprised of permanently asymptomatic 71 infected individuals. Such models have been used to analyze testing, contact tracing, and quar-72 antine control strategies (16, 17), particularly in the context of limited resource constraints (18), 73 along with vaccination control (19) and non-pharmaceutical interventions like masking and social 74 distancing (20, 21). Although useful as simple baseline examples, these models may overestimate 75 the efficacy of symptom-based COVID-19 controls due to the absence of presymptomatic transmis-76 sion. A second more complicated class of ODE models includes a presymptomatic compartment 77 where individuals are infectious but not yet symptomatic before transitioning to an infectious 78 symptomatic compartment (22, 23, 24, 25). This approach, while more realistic, presents chal-79 lenges when interpreting results for real world decision making via comparisons to the simpler class 80 of models. Specifically, when multiple infectious stages are incorporated into an ordinary differ-81 ential equation model, the total infectious period is no longer exponentially distributed (as would 82 occur for a single infectious stage), but is instead more similar to a gamma or Weibull distribu-83 tion (26), and such non-exponential distributions have been shown to be more difficult to control 84 with identification-isolation strategies as compared to exponential distributions (27). Thus, it is 85 unclear to what degree differences in output between models with and without presymptomatic 86 compartments are due to presymptomatic transmission itself or to the presence of non-exponential 87

infectious periods, and this presents a barrier to interpreting model results for real-world decision 88 making. Furthermore, when a totally asymptomatic infection channel is included, one must either 89 add a fictitious presymptomatic compartment for this class or accept a major qualitative difference 90 between the infectious period distributions of those who will never and those who will eventually 91 show symptoms (exponential vs non-exponential). Either option may have important impacts on 92 model behavior, yet to our knowledge, this issue may has not been explicitly addressed in the 93 literature. Finally, the class of models with presymptomatic compartments can not be adapted 94 to other diseases for which infectiousness peaks well after symptom onset (such as with the 2003) 95 SARS coronavirus (28, 29)) without significant changes to model structure, and this complicates 96 any comparative mathematical analysis of diseases which are fundamentally similar to one another 97 aside from changes in latent-incubation period mismatch. This deficit may be particularly prob-98 lematic for utilizing mathematical models to inform real-world control strategies for new emerging 99 epidemics based on the lessons learned from COVID-19. 100

We address these shortcomings by developing a partial integro differential equation model which 101 utilizes the age of infection to decouple symptom status from specific model compartments. Our 102 model is general in its ability to incorporate any latent, incubation, and infectious period distri-103 bution, regardless of shape or relative timings of means, and is utilized to analyze the original. 104 delta, and omicron variants as well as a spectrum of other generically parameterized diseases all 105 under a single lens. We incorporate a testing and quarantine control strategy which uses testing 106 resources to identify infected individuals and remove them from the population while accounting 107 for factors like contact tracing, limited population accessibility, and biases towards test-positive 108 results. Our control assumes a fixed maximum testing capacity that must be allocated between 109 clinical testing targeted at symptomatic individuals and non-clinical testing targeted at pre- and 110 asymptomatic individuals. We analyze how controllability and optimal allocation strategies for 111 reducing total infection size behave as functions of resource availability, testing quality, and dis-112 ease characteristics. In general, we find that most factors that reduce controllability also call for 113 a smaller share of resources to be devoted to non-clinical testing in optimal strategies. However, 114 although presymptomatic transmission is found to reduce controllability, whether or not it reduces 115 the role of non-clinical testing in optimal strategies depends on a complicated relationship between 116 latent-incubation offset, disease transmissibility, and latent period length. In particular, we find 117

that diseases with presymptomatic transmission do not necessarily call for a increase in non-clinical testing resource allocation compared to diseases lacking presymptomatic transmission, despite the fact that intuition would deem non-clinical testing to be of greater importance due to its the potential to eliminate presymptomatic spreaders. Together, these results highlight how intuition for disease control strategies based on qualitative disease characteristics may fail and thus emphasize the need for mathematical modeling to prepare for and manage future epidemics.

## $_{124}$ 2 Methods

We extend the previous ordinary differential equation (ODE) SEIR testing and quarantine model of Calabrese and Demers (18) to a system of integro-partial differential equations (IPDE) which explicitly incorporate the age of infection for infected classes. While our primary focus is COVID-19, including the original, delta, and omicron variants, our system is general in its ability to account for any set of latent, incubation, and infectiousness periods.

## 130 2.1 Model outline

#### 131 2.1.1 Uncontrolled transmission model

We assume a homogeneously mixed system of N total susceptible, exposed, infectious, and recovered 132 individuals. Exposed and infectious classes are partitioned into those who will remain permanently 133 asymptomatic throughout the course of the infection and those who will eventually become symp-134 tomatic at some point before recovery. Here, we take "asymptomatic" to mean genuinely exhibiting 135 no symptoms or exhibiting symptoms so minor that one would not typically consider themselves ill 136 or seek medical attention, and "symptomatic" to mean exhibiting visually identifiable symptoms 137 with moderate to critical illness. Upon infection, initially susceptible individuals S will enter either 138 the exposed permanently asymptomatic class  $E_A$  or the exposed eventually symptomatic class  $E_Y$ 139 with probabilities  $f_A$  and  $f_Y$ , respectively (throughout this paper, we use the abbreviations PA 140 and ES to denote permanently asymptomatic and eventually symptomatic individuals). While in 141 an exposed class, individuals are infected but not yet infectious and are thus unable to transmit 142 the disease to others. To account for the possibility of non-exponential waiting times between 143 infection sages, we continuously index exposed classes with the age of infection x. The number of 144

individuals in the exposed PA class at time t who have been infected between x and x + dx units 145 of time is denoted  $e_A(t, x)dx$  such that the total number of exposed PA individuals  $E_A(t)$  is given 146 by  $E_A(t) = \int_0^\infty dx \, e_A(t,x)$ . The age of infection-indexed exposed ES class  $e_Y(t,x)$  is defined analo-147 gously. PA and ES exposed individuals with infection age x transition to their respective infectious 148 classes a(t,x) and y(t,x) at rate  $\varepsilon(x)$ . Infectious individuals enter into the recovered class R where 149 they are no longer infectious and are assumed to attain permanent immunity at age of infection 150 dependent recovery rate r(x). Although there is some evidence suggesting that ES and PA indi-151 viduals recover from COVID-19 at different rates, disease progression in asymptomatic individuals 152 is poorly understood, and conflicting studies have shown faster, similar, and slower viral clearance 153 rates in asymptomatic versus symptomatic cases (30, 31). For simplicity, we therefore take r(x)154 to be equivalent for PA and ES infections. Likewise, we are aware of only one study suggesting 155 different transitions rates from the exposed to infectious class for PA versus ES individuals (10), 156 but the corresponding average waiting times differ by only 5%, so we assume exposed to infectious 157 transition rates to be independent of the eventual presence or lack of symptoms. The dynamical 158 equations for the uncontrolled transmission model are as follows: 159

$$\dot{S}(t) = -\lambda_A \beta \frac{A(t)}{N} S(t) - \lambda_Y \beta \frac{Y(t)}{N} S(t)$$
(1a)

$$\partial_t e_A(t, x) + \partial_x e_A(t, x) = -\varepsilon(x) e_A(t, x)$$
 (1b)

$$e_A(t,0) = f_A\left(\lambda_A \beta \frac{A(t)}{N} S(t) + \lambda_Y \beta \frac{Y(t)}{N} S(t)\right)$$
(1c)

$$\partial_t e_Y(t, x) + \partial_x e_Y(t, x) = -\varepsilon(x) e_Y(t, x)$$
 (1d)

$$e_Y(t,0) = f_Y\left(\lambda_A \beta \frac{A(t)}{N} S(t) + \lambda_Y \beta \frac{Y(t)}{N} S(t)\right)$$
(1e)

$$\partial_t a(t,x) + \partial_x a(t,x) = \varepsilon(x) e_A(t,x) - r(x)a(t,x)$$
 (1f)

$$(t,0) = 0 \tag{1g}$$

$$\partial_t y(t,x) + \partial_x y(t,x) = \varepsilon(x) e_Y(t,x) - r(x)y(t,x)$$
 (1h)

$$y(t,0) = 0 \tag{1i}$$

$$\dot{R}(t) = \int_0^\infty dx \left( r(x)a(t,x) + r(x)y(t,x) \right)$$
(1j)

160

$$E_A(t) = \int_0^\infty dx \, e_A(t, x), \quad E_Y(t) = \int_0^\infty dx \, e_Y(t, x),$$
 (1k)

a

$$A(t) = \int_0^\infty dx \, a(t,x), \quad Y(t) = \int_0^\infty dx \, y(t,x).$$

In the above equations, overdots denote ordinary derivatives with respect to time t,  $\beta$  denotes the 161 average number of contacts made per unit time by an individual, N is the total population size, and 162  $\lambda_A$  and  $\lambda_Y$  denote the transmission probability per susceptible-infectious contact for the PA and 163 ES classes, respectively (for simplicity, we assume transmission probability to be independent of 164 the age of infection). The boundary terms  $e_A(t,0)$  and  $e_Y(t,0)$  denote the rates of newly generated 165 infections and thus represent to individuals with infection age x = 0. The boundary terms a(t, 0)166 and y(t,0) are zero due to the fact that every infected individual will spend at least some time in an 167 exposed class before becoming infectious and will therefore never enter an infectious class with an 168 infection age x = 0. The integrals in Eq. (1k) relate the total number of individuals in an infected 169 class to the corresponding distribution over the age of infection. 170

### 171 2.1.2 Symptom onset

The model in Eq. (1) makes no assumptions regarding the onset of symptoms in infected individ-172 uals. This modeling choice is based on the fact that the natural dynamics of disease transmission 173 (absent interventions or controls explicitly correlated with symptom status) depend fundamentally 174 on infectious states rather than symptom states. In our IPDE model, symptoms are an incidental 175 background state which need not be represented by separate pre- and post-symptom onset com-176 partments for each infected compartment as would be required in an ordinary differential equation 177 (ODE) model. We utilize the age of infection in the ES classes to the define the symptomatic 178 population  $X_S(t)$  by the following integral: 179

$$X_{S}(t) = \int_{0}^{\infty} dx \Big( P_{e}(x)e_{Y}(t,x) + P_{y}(x)y(t,x) \Big).$$
(2)

The functions  $P_e(x)$  and  $P_y(x)$  denote the respective probabilities for exposed and infectious individuals to show symptoms by infection day x. These probabilities likewise determine the nonsymptomatic infected population  $X_N(t)$  as follows:

$$X_N(t) = E_A(t) + A(t) + \int_0^\infty dx \Big( \big(1 - P_e(x)\big) e_Y(t, x) + \big(1 - P_y(x)\big) y(t, x) \Big).$$
(3)

The non-symptomatic infected population is comprised of all PA infected individuals plus the ES infected individuals who are not yet showing symptoms.

In our simulations, we consider two assumptions for  $P_e(x)$  and  $P_y(x)$ , "correlated symptoms" and "incubation symptoms:"

Correlated Symptoms: 
$$P_e(x) = 0, P_y(x) = 1.$$
 (4)  
Incubation Symptoms:  $P_e(x) = P_y(x) = \int_0^x dx' f_I(x').$ 

The correlated symptoms assumption defines symptom onset to occur in perfect correlation with 187 infectiousness onset. Here, there is no possibility of pre-symptomatic transmission or pre-infectious 188 symptom onset, and the symptomatic population is the entire ES infectious class. This assumption 189 is equivalent to the symptom assumptions of our previous ODE testing and quarantine COVID-19 190 model in (18). The incubation symptoms assumptions defines  $P_e(x)$  and  $P_y(x)$  to be the cumu-191 lative distribution function of an incubation period distribution  $f_I(x)$ . Here,  $f_I(x)dx$  denotes the 192 probability for an ES individual to begin showing symptoms between age of infection x and x + dx. 193 The flow diagram in Fig. 1 summarizes the progression of infectious and symptomatic states in the 194 uncontrolled transmission model. 195



Figure 1: Schematic indicating the flow of infectious and symptomatic states in our uncontrolled transmission model. Upon infection, susceptible individuals S move into either the permanently asymptomatic (PA) exposed class  $E_A$  or the eventually symptomatic (ES) exposed class  $E_Y$  with an initial age of infection x = 0. As individuals linger in the exposed classes, their ages of infection increase, and transitions to the PA infectious class A and ES infectious class Y occur at infection age dependent transition rate  $\varepsilon(x)$  Infectious individuals then transition to the recovered class Rat the infection-age-dependent transition rate r(x). Symptom status appears as background state indicated by the red and green boxes. For ES exposed and infectious individuals with infection age x, a fraction  $P_e(x)$  and  $P_y(x)$ , respectively, will be in the symptomatic state  $X_S$ , while the remaining fractions  $1 - P_e(x)$  and  $1 - P_y(x)$  will be in the non-symptomatic state  $X_N$ . The PA classes  $E_A$  and A remain in the non-symptomatic state  $X_N$  until recovery.

### <sup>196</sup> 2.1.3 Testing and quarantine transmission model

We adapt the resource allocation testing and quarantine control framework from the ODE model of 197 (18) to our IPDE disease model. Testing identifies and transfers infected individuals to a quarantine 198 class Q where they remain isolated from contacts until recovery and are unable to generate new 199 transmissions. We assume a finite testing resource represented by the testing capacity C, defined 200 as the maximum per capita number of tests able to be administered and processed per day. A frac-201 tion  $\rho$  of the testing capacity is allocated to non-clinical testing for identifying non-symptomatic 202 infected individuals, while the remaining fraction  $1-\rho$  is allocated to clinical testing for identifying 203 symptomatic infected individuals. Clinical testing is conducted only on individuals showing suffi-204 ciently severe visually identifiable symptoms, while non-clinical testing is accessible to the general 205 public. The actual rate at which tests are administered and processed for the two testing categories 206 is dependent on the *testing demand*, i.e. on the number of people eligible for and actively seeking 207 testing. Here, we provide the functional forms of test administration and processing rates for clini-208 cal and non-clinical testing and sketch the reasoning behind their formulation. Further details are 209 elucidated in (18). 210

The average time required for a non-clinical test to be administered and processed for a single individual is denoted  $\tau_N$  such that the average administration and processing rate is given by  $1/\tau_N$ :

$$\tau_N^{-1} = \begin{cases} 0, & C = 0 \text{ or } \rho = 0\\ \left[\tau + \kappa \frac{X_N(t) + \left(1 - \eta\right) \left(S(t) + U(t)\right)}{\rho CN}\right]^{-1}, & \text{otherwise} \end{cases}$$
(5)

Non-clinical testing enters the disease model by transferring a fraction  $\kappa$  of the non-symptomatic 213 infected population (either pre- or asymptomatic) to the quarantined class Q at rate  $\tau_N^{-1}$ . The case 214 C = 0 corresponds to no testing capacity and thus no control, while the case  $\rho = 0$  corresponds to 215 all resources being devoted to clinical testing which reduces the non-clinical testing rate to zero. 216 The quantity  $\tau$  is the *intrinsic testing time*, defined as average time required for an individual get 217 to a testing center, get tested, and receive results absent of delays or backlogs due to other patents. 218 We take this value to be equal to one day. The testing demand for non-clinical testing is defined 219 as a fraction  $\kappa$  the non-symptomatic population  $X_N(t)$  in Eq. (3) as well as a fraction  $\kappa(1-\eta)$ 220 of the uninfected population S(t) + U(t). Here, U(t) represents individuals who were previously 221

infected and subsequently recovered without being tested and are thus unaware that they have 222 immunity (we assume recovered individuals who were tested and guarantined know that they 223 have immunity and therefore exclude themselves from future testing). The accessibility parameter 224  $\kappa \in (0,1]$  represents the fraction of the total population open to and compliant with non-clinical 225 testing, and the concentration parameter  $\eta \in [0, 1)$  represents the degree to which testing is focused 226 on or biased towards infected individuals. A purely random population monitoring program which 227 reaches all members of the population corresponds to  $\kappa = 1$  and  $\eta = 0$ . Any factor that influences 228 a given test such that it will be more likely applied to an infected individual as compared to purely 229 random sampling will increase  $\eta$ . For example, those who suspect a recent disease exposure may 230 be both more likely to seek testing and more likely to test positive compared a randomly selected 231 individual, and this influence will focus testing towards the  $X_N$  population and away from the S+U232 population. Likewise, a highly effective contact tracing program may result in a relatively large 233 value of  $\eta$ , but there may be many individuals unwilling to participate in government or health 234 agency efforts, so the corresponding value of  $\kappa$  may be relatively small. Generally, the differing 235 behavioral characteristics of individuals and differing testing policies of local governments unique 236 to differing regions will correspond to a variety of concentration and accessibility levels, so we will 237 analyze model results for a wide array of  $\kappa$  and  $\eta$  values. The analysis in (18) shows that  $\eta$  can be 238 estimated from data comparing test-positive to disease prevalence rates, and that  $\eta = 0.95$  is an 239 upper bound on optimistically achievable values. 240

The average time required for a clinical test to be administered and processed for a single symptomatic individual is denoted  $\tau_C$  such that the average administration and processing rate is given by  $1/\tau_C$ :

$$\tau_{C}^{-1} = \begin{cases} 0, & C = 0 \text{ or } \rho = 1 \\ \left[\tau + \frac{X_{S}(t)}{(1-\rho)CN}\right]^{-1}, & \text{otherwise} \end{cases}$$
(6)

Clinical testing enters the disease model by transferring symptomatic individuals to the quarantine class Q at rate  $\tau_C^{-1}$ . The case C = 0 corresponds to no control, while the case  $\rho = 1$  corresponds to all resources being devoted to non-clinical testing which reduces the clinical testing rate to zero. In contrast to non-clinical testing, clinical testing is assumed to have full concentration on and full

accessibility to the target infected population, meaning that the testing demand is comprised only of the symptomatic population  $X_S$  and includes no uninfected individuals. We base this on the assumption that all individuals in the ES classes who are currently showing symptoms are all ill enough to seek medical attentions (full advisability), and that due to the presence of strong visually identifiable symptoms and the lack of secondary diseases in our model, there is no chance of using a clinically allocated test on an uninfected individual (full concentration). In this sense, clinical testing acts as a verification tool, while non-clinical testing acts as an identification tool.

For both testing types, when testing demand is very low, tests are administered and processed 255 at maximum rates  $\tau_C^{-1} \approx \tau^{-1}$  and  $\tau_N^{-1} \approx \tau^{-1}$  per individual, and the total number of clinical 256 tests conducted per day grows linearly with the size of the symptomatic population. As demand 257 increases, supply limitations and patient backlogs cause  $\tau_C^{-1}$  and  $\tau_N^{-1}$  to decrease towards zero, and 258 the total number of clinical and non-clinical tests conducted per day saturates to  $(1 - \rho)CN$  and 259  $\rho CN$ , respectively, as testing demand approaches infinity. The full model equations with testing 260 and quarantine control are given in Eq. (7) and a corresponding flow diagram is given in Fig. 2. 261 Table 1 summarizes the definitions of all control-related parameters. 262

$$\dot{S}(t) = -\lambda_A \beta \frac{A(t)}{N - Q(t)} S(t) - \lambda_Y \beta \frac{Y(t)}{N - Q(t)} S(t)$$
(7a)

$$\partial_t e_A(t,x) + \partial_x e_A(t,x) = -\varepsilon(x) e_A(t,x) - \kappa \tau_N^{-1} e_A(t,x)$$
(7b)

1

e

$$A(t,0) = f_A\left(\lambda_A \beta \frac{A(t)}{N - Q(t)} S(t) + \lambda_Y \beta \frac{Y(t)}{N - Q(t)} S(t)\right)$$
(7c)

$$\partial_t e_Y(t,x) + \partial_x e_Y(t,x) = -\varepsilon(x) e_Y(t,x) - \tau_C^{-1} P_e(x) e_Y(t,x)$$
(7d)

$$-\tau_N^{-1}\kappa (1 - P_e(x))e_Y(t, x)$$

$$e_Y(t, 0) = f_Y\left(\lambda_A \beta \frac{A(t)}{N - Q(t)}S(t) + \lambda_Y \beta \frac{Y(t)}{N - Q(t)}S(t)\right)$$
(7e)

$$\partial_t a(t,x) + \partial_x a(t,x) = \varepsilon(x) e_A(t,x) - r(x)a(t,x) - \tau_N^{-1} \kappa a(t,x)$$
(7f)

$$a(t,0) = 0 \tag{7g}$$

$$\partial_t y(t,x) + \partial_x y(t,x) = \varepsilon(x) e_Y(t,x) - r(x)y(t,x) - \tau_C^{-1} P_y(x)y(t,x)$$

$$-\tau_N^{-1} \kappa (1 - P_y(x))y(t,x)$$
(7h)

$$y(t,0) = 0 \tag{7i}$$

$$\partial_t q(t,x) + \partial_x q(t,x) = -r(x)q(t,x) + \tau_C^{-1} \Big[ P_e(x)e_Y(t,x) + P_y(x)y(t,x) \Big]$$
(7j)

$$+\tau_N^{-1}\kappa\Big[e_A(t,x) + a(t,x) + (1 - P_e(x))e_Y(t,x) + (1 - P_y(x))y(t,x)\Big]$$

$$= 0$$
(71)

$$q(t,0) = 0$$
(7k)  
$$\dot{U}(t) = \int_{-\infty}^{\infty} dx \left( r(x)a(t,x) + r(x)y(t,x) \right)$$
(7l)

$$\dot{R}(t) = \int_{0}^{\infty} dx \left( r(x)a(t,x) + r(x)y(t,x) + r(x)q(t,x) \right)$$
(7m)

263

$$E_A(t) = \int_0^\infty dx e_A(t, x), \quad E_Y(t) = \int_0^\infty dx e_Y(t, x),$$
(7n)  
$$A(t) = \int_0^\infty dx a(t, x), \quad Y(t) = \int_0^\infty dx y(t, x), \quad Q(t) = \int_0^\infty dx q(t, x).$$

Parameter	Name	Meaning
C	Testing capacity	Maximum number of tests able to
		be administered and processed per
		day per capita
$\tau$	Testing time	Average amount of time required for
		an individual be tested (including
		procrastination, travel time, pro-
		cessing time, etc.) absent of back-
		logs or delays due to other patients
ρ	Strategy parameter	Fraction of testing capacity devoted
		to non-clinical testing
$\eta$	Concentration parameter	$(1 - \eta)$ = Degree to which non-
		clinical testing resources are utilized
		on uninfected individuals
$\kappa$	Accessibility parameter	Fraction of eligible population open
		to and compliant with non-clinical
		testing

Table 1: Testing and quarantine control parameter definitions

264



Figure 2: Flow diagram for the testing and quarantine control model in Eq. (7). The symptomatic population  $X_S$  and fraction  $\kappa$  of the non-symptomatic population  $X_N$  transition to the quarantine class Q by clinical and non-clinical testing, respectively, at rates  $\tau_C^{-1}$  and  $\tau_N^{-1}$ . Quarantined individuals transition to the recovered class R at age of infection dependent rate r(x). The subset U of the recovered class represents individuals who were previously infected and subsequently recovered without testing and quarantine and are thus unaware that they have obtained immunity.

### 265 2.1.4 Transition rates

The transition rates  $\varepsilon(x)$  and r(x) are determined by probability distributions for infection ages at which transitions between disease states occur. Specifically, letting  $f_{\varepsilon}(x)$  denote the probability density for an infected individual to transition from exposed to infectious at infection age x, and letting  $f_r(x)$  denote the probability density for an infectious individual to transition to recovered at infection age x, the corresponding transition rates are defined as follows:

$$\varepsilon(x) = \frac{f_{\varepsilon}(x)}{1 - \int_0^x dx' f_{\varepsilon}(x')},\tag{8}$$

$$r(x) = \frac{f_r(x)}{1 - \int_0^x dx' f_r(x)}.$$
(9)

These transition rates represent conditional probability densities for an individual to transition to the next disease stage on infection day x given that they are still in the preceding disease stage up to day x. The probability densities for the infectious period duration and total infection duration, denoted  $f_{inf}(x)$  and  $f_{tot}(x)$ , respectively, can be written in terms of  $f_{\varepsilon}(x)$  and  $f_r(x)$  as follows:

$$f_{inf}(x) = \int_0^\infty ds \, f_{\varepsilon}(s) \frac{f_r(x+s)}{1 - \int_0^s ds' \, f_r(s')},\tag{10}$$

$$f_{tot}(x) = \int_0^x ds \, f_{\varepsilon}(s) \frac{f_r(x)}{1 - \int_0^s ds' \, f_r(s')}.$$
 (11)

To clarify,  $f_{tot}(x)dx$  represents the probability for an newly infected individual to remain infected for 275 a total duration between x and x + dx days,  $f_{inf}(x)dx$  represents the probability for that individual 276 to be infectious (i.e. contagious) for a total duration between x and x + dx days over the course 277 of their infection, and  $f_r(x)dx$  represents the probability for that individual to recover between 278 infection days x and x + dx given that they have already entered into an infectious state. If  $f_r(x)$  is 279 assumed to be an exponential distribution with mean 1/r, r(x) reduces to a constant r(x) = r while 280  $f_{inf}(x)$  becomes equivalent to  $f_r(x)$ . Likewise, if  $f_{\varepsilon}(x)$  is exponential with mean  $1/\varepsilon$ ,  $\varepsilon(x)$  reduces 281 to a constant  $\varepsilon(x) = \varepsilon$ . If both  $f_r(x)$  and  $f_{\varepsilon}(x)$  are exponential,  $f_{tot}(x)$  becomes a two parameter 282 hypoexponential distribution with parameters  $\varepsilon$  and r. The exponential distribution assumptions 283 taken together with the correlated symptoms assumption in Sec. 2.1.2 reduce the IPDE testing and 284 quarantine model in Eq. (7) to the ODE testing and quarantine model in (18). 285

## 286 2.2 Distribution and parameter values

#### 287 2.2.1 COVID-19 variants

The distributions from which the transition rates  $\varepsilon(x)$  and r(x) are calculated, as well as the incu-288 bation period distribution, are based on epidemiological data for the original, delta, and omicron 289 COVID-19 variants. The incubation period distribution  $f_I(x)$  is a widely studied quantity for the 290 early strains of COVID-19 which has been variously fit to log-normal, gamma, or Weibull distri-291 butions (32, 33, 34, 35, 36, 37). The latent period distribution  $f_{\varepsilon}(x)$  and post-infectiousness onset 292 recovery day distribution  $f_r(x)$  are comparatively less well studied. For the original COVID-19 293 strain and delta variant, we utilize the results of Xin et al. (10) and Kang et al. (11), respectively, 294 which estimate both  $f_{\varepsilon}$  and  $f_{I}$  to be gamma distributions. We are aware of only one data-based 295 study estimating the incubation period distribution for the omicron variant, Tanaka et al. (38), 296 which fits to a log-normal distribution with median 2.8 days. Other investigations estimating me-297 dians but not distributions have likewise obtained results approximately equal to 3 days (39, 40). To 298 maintain consistency with the original and delta variants, we assume  $f_I$  for omicron to be gamma 299 distributed with mean and variance comparable to that of (38). We are unaware of any existing 300 estimates for the omicron variant's latent period distribution, so we assume a gamma distribution 301 with mean 1.5 days shorter than that of the incubation period. For all variants, we are unaware 302 of any studies that directly estimate the post-infectiousness onset recovery day distribution  $f_r(x)$ . 303 However, viral culturing studies have consistently found live viral isolation to cease between 9 and 304 10 days post-symptom onset (30, 31, 41). We therefore assume a gamma distribution for  $f_r(x)$  with 305 mean  $\langle f_r \rangle = \langle f_I \rangle + 9.5$  days for each variant, and we assume a scale parameter of 0.25 days to give 306 tight distributions with relatively small interquartile ranges as indicted in (41). 307

To assess the impact of the PDE elements of our model relative to the corresponding ODE model, we will compare simulation results under exponential and gamma distribution assumptions for  $f_{\varepsilon}$  and  $f_r$ . Likewise, to assess the impact of pre-symptomatic transmission on disease controllability, we will compare model results between the correlated symptoms and incubation symptoms assumptions in Eq. (4). The means  $\langle f_{\varepsilon} \rangle$  are taken to be equivalent under the exponential and gamma assumptions, while we set  $\langle f_r \rangle = \langle f_I \rangle - \langle f_{\varepsilon} \rangle + 9.5$  days under the exponential assumption as compared to  $\langle f_r \rangle = \langle f_I \rangle + 9.5$  days under the gamma assumption. This difference ensures that

the mean infectious period duration  $\langle f_{inf} \rangle$  and mean total infection time  $\langle f_{tot} \rangle$  are essentially un-315 changed by the different assumptions on  $f_r$ . The means and standard deviations of  $f_{\varepsilon}$ ,  $f_r$ , and  $f_I$ , 316 as well as that of the resultant distributions  $f_{inf}$  and  $f_{tot}$ , are given in Tables 2, 3, and 4 for the 317 original, delta, and omicron COVID variants, respectively. Plots depicting the shapes of  $f_{\varepsilon}, f_r$ , 318 and  $f_I$  for the three variants are given in Fig. 3. For all variants and distribution assumptions, 319 the average infectious period is approximately 11 days while the average latent period is approx-320 imately 1.5 days shorter than the average incubation period, thus indicating an average 1.5 day 321 presymptomatic transmission window under the incubation symptoms assumption. The mean total 322 infection duration decreases from the original to delta to omicron variant. 323

The remaining model parameters and values are summarized in Table 5. For all COVID vari-324 ants, the PA and ES population fractions,  $f_A$  and  $f_Y$ , respectively, are highly uncertain parameters, 325 as estimates based on both modeling and clinical data place  $f_A$  anywhere from less than 1% to 326 90% (12, 13, 14, 15). Further, the value of  $f_A$  will depend precisely on our definition of the differ-327 ence between the moderate to critical symptoms exhibited by the ES class versus the mild to no 328 symptoms exhibited by the PA class. Evidence has suggested the majority of COVID cases to be 329 mild (42, 43), so based on these observations, we choose  $f_A = 0.75$  and  $f_Y = 0.25$ . Likewise, the 330 relative values of the PA and ES transmission probabilities,  $\lambda_A$  and  $\lambda_Y$ , respectively, are highly 331 uncertain. Various studies have show that non-symptomatic individuals are as, or less, infectious 332 than symptomatic individuals (13, 14), and that greater symptom severity correlates with higher 333 viral loads (13, 14, 42). Further, a study on the close contacts of index cases has suggested symp-334 tomatic individuals to be more infectious than asymptomatic individuals (44). We therefore assume 335  $\lambda_Y = 2\lambda_A$ . To determine absolute values, we assume an average contact rate of  $\beta = 4$  per day 336 and scale  $\lambda_A$  such that the model's uncontrolled basic reproduction number under the exponential 337 distribution assumptions (i.e. equivalent ODE model), denoted  $R_0^{un}$ , matches values taken from the 338 literature (see the Supplementary Material section S1 and S2 for a derivation and discussion of the 339 basic reproduction number). In other words, we define the following quantity: 340

$$R_0^{un} = f_A \frac{\beta \lambda_A}{r} + (1 - f_A) \frac{\beta \lambda_Y}{r}, \qquad (12)$$

and then choose  $\lambda_A$  such that the above expression matches values for the different COVID variants, 341 where the values of  $f_A$  and  $\beta$  are assumed, 1/r is equal to  $\langle f_{inf} \rangle$  under the exponential distributions 342 assumptions in Tables 2, 3, or 4, and where we assume  $\lambda_Y = 2\lambda_A$ . Based on estimates of  $R_0$  during 343 the initial phases of the pandemic (45, 46, 47), we set  $R_0^{un} = 3.0$  for the original COVID variant. 344 Combining estimates from (11, 48, 49), we set  $R_0^{un} = 6.4$  for the delta variant. Based on (49, 50), we 345 set  $R_0^{un} = 9.5$  for the omicron variant. We note that changing exponential or gamma distribution 346 assumptions for  $f_r$  and  $f_{\varepsilon}$  have a negligible impact on actual model basic reproduction number (see 347 Supplementary Material section S2), so  $R_0^{un}$  represents the uncontrolled basic reproduction number 348 for all distribution and symptom onset assumptions.

Original Variant	$f_{\varepsilon}$ Gamma Distribution		$f_{\varepsilon}$ Exponential Distribution	
	$\langle f_{\varepsilon} \rangle = 5.48$	$\sigma_{\varepsilon} = 2.72$	$\langle f_{\varepsilon} \rangle = 5.48$	$\sigma_{\varepsilon} = 5.48$
f Gamma Distribution	$\langle f_r \rangle = 16.38$	$\sigma_r = 2.02$	$\langle f_r \rangle = 16.38$	$\sigma_r = 2.02$
$j_r$ Gamma Distribution	$\langle f_{inf} \rangle = 10.92$	$\sigma_{inf} = 3.34$	$\langle f_{inf} \rangle = 11.26$	$\sigma_{inf} = 4.81$
	$\langle f_{tot} \rangle = 16.40$	$\sigma_{tot} = 2.02$	$\langle f_{tot} \rangle = 16.74$	$\sigma_{tot} = 2.69$
	$\langle f_{\varepsilon} \rangle = 5.48$	$\sigma_{\varepsilon} = 2.72$	$\langle f_{\varepsilon} \rangle = 5.48$	$\sigma_{\varepsilon} = 5.48$
f Exponential Distribution	$\langle f_r \rangle = 10.90$	$\sigma_r = 10.90$	$\langle f_r \rangle = 10.90$	$\sigma_r = 10.90$
$J_r$ Exponential Distribution	$\langle f_{inf} \rangle = 10.90$	$\sigma_{inf} = 10.90$	$\langle f_{inf} \rangle = 10.90$	$\sigma_{inf} = 10.90$
	$\langle f_{tot} \rangle = 16.38$	$\sigma_{tot} = 11.23$	$\langle f_{tot} \rangle = 16.38$	$\sigma_{tot} = 12.20$
$f_I$ Gamm	$\langle f_I \rangle = 6.88$	$\sigma_I = 3.32$		

Table 2: Original variant distributions based on Refs. (30, 31, 10, 41). Simulations assume either exponential or gamma distributions for  $f_{\varepsilon}$  and  $f_r$  with means  $\langle \rangle$  and standard deviations  $\sigma$  as indicated in units of days. Means and standard deviations for the resulting infectious period distribution  $f_{inf}$  and total infection duration distribution  $f_{tot}$  are likewise indicated. The incubation symptoms assumption utilizes a gamma distributed incubation period length  $f_I$  with indicated mean and standard deviation in units of days.

349

Delta Variant	$f_{\varepsilon}$ Gamma Distribution		$f_{\varepsilon}$ Exponential Distribution	
	$\langle f_{\varepsilon} \rangle = 4.00$	$\sigma_{\varepsilon} = 2.22$	$\langle f_{\varepsilon} \rangle = 4.00$	$\sigma_{\varepsilon} = 4.00$
f Camma Distribution	$\langle f_r \rangle = 15.30$	$\sigma_r = 1.96$	$\langle f_r \rangle = 15.30$	$\sigma_r = 1.96$
$J_r$ Gamma Distribution	$\langle f_{inf} \rangle = 11.30$	$\sigma_{inf} = 2.94$	$\langle f_{inf} \rangle = 11.43$	$\sigma_{inf} = 4.02$
	$\langle f_{tot} \rangle = 15.30$	$\sigma_{tot} = 1.96$	$\langle f_{tot} \rangle = 15.43$	$\sigma_{tot} = 2.14$
	$\langle f_{\varepsilon} \rangle = 4.00$	$\sigma_{\varepsilon} = 2.22$	$\langle f_{\varepsilon} \rangle = 4.00$	$\sigma_{\varepsilon} = 4.00$
f Exponential Distribution	$\langle f_r \rangle = 11.30$	$\sigma_r = 11.30$	$\langle f_r \rangle = 11.30$	$\sigma_r = 11.30$
$J_r$ Exponential Distribution	$\langle f_{inf} \rangle = 11.30$	$\sigma_{inf} = 11.30$	$\langle f_{inf} \rangle = 11.30$	$\sigma_{inf} = 11.30$
	$\langle f_{tot} \rangle = 15.30$	$\sigma_{tot} = 11.51$	$\langle f_{tot} \rangle = 15.30$	$\sigma_{tot} = 11.99$
$f_I$ Gamm	$\langle f_I \rangle = 5.80$	$\sigma_I = 3.02$		

Table 3: Delta variant distributions based on Refs. (30, 31, 11, 41). Meanings of quantities are as described in Table 2.

Omicron Variant	$f_{\varepsilon}$ Gamma Distribution		$f_{\varepsilon}$ Exponential Distribution		
	$\langle f_{\varepsilon} \rangle = 1.50$	$\sigma_{\varepsilon} = 1.00$	$\langle f_{\varepsilon} \rangle = 1.50$	$\sigma_{\varepsilon} = 1.50$	
f Gamma Distribution	$\langle f_r \rangle = 12.50$	$\sigma_r = 1.77$	$\langle f_r \rangle = 12.50$	$\sigma_r = 1.77$	
$J_r$ Gamma Distribution	$\langle f_{inf} \rangle = 11.00$	$\sigma_{inf} = 2.03$	$\langle f_{inf} \rangle = 11.00$	$\sigma_{inf} = 2.31$	
	$\langle f_{tot} \rangle = 12.50$	$\sigma_{tot} = 1.77$	$\langle f_{tot} \rangle = 12.50$	$\sigma_{tot} = 1.77$	
	$\langle f_{\varepsilon} \rangle = 1.50$	$\sigma_{\varepsilon} = 1.00$	$\langle f_{\varepsilon} \rangle = 1.50$	$\sigma_{\varepsilon} = 1.50$	
f Exponential Distribution	$\langle f_r \rangle = 11.00$	$\sigma_r = 11.00$	$\langle f_r \rangle = 11.00$	$\sigma_r = 11.00$	
$J_r$ Exponential Distribution	$\langle f_{inf} \rangle = 11.00$	$\sigma_{inf} = 11.00$	$\langle f_{inf} \rangle = 11.00$	$\sigma_{inf} = 11.00$	
	$\langle f_{tot} \rangle = 12.50$	$\sigma_{tot} = 11.04$	$\langle f_{tot} \rangle = 12.50$	$\sigma_{tot} = 11.10$	
$f_I$ Gamm	$\langle f_I \rangle = 3.00$	$\sigma_I = 1.22$			

Table 4: Omicron variant distributions based on Refs. (30, 31, 38, 41). Meanings of quantities are as described in Table 2



Figure 3: Latent period distributions  $f_{\varepsilon}(x)$ , incubation period distributions  $f_I(x)$ , and postinfectiousness onset recovery day distributions  $f_r(x)$  as functions of the age of infection x for the original, delta, and omicron variants of COVID-19. Model simulations will consider combinations of exponential (dotted lines) and gamma (solid lines) distribution assumptions for  $f_{\varepsilon}$  and  $f_r$ , as well as an incubation period symptom onset assumption using a gamma distribution for  $f_I$  or a correlated symptom assumption where symptom onset coincides exactly with the onset of infectiousness.

#### 350 2.2.2 Generic diseases

In addition to the COVID-19 variants, we consider a generic disease similar to the original variant 351 but with a variable offset between the mean incubation and latent period. Defining  $z = \langle f_I \rangle - \langle f_{\varepsilon} \rangle$ , 352 we consider both positive and negative z values. Positive z values represent diseases for which 353 symptom onset typically occurs after infectiousness onset, thus allowing for significant levels of pre-354 symptomatic transmission as occurs, for example, with the viruses SARS-CoV-2 and 2009 pandemic 355 influenza H1N1 (51, 52, 28). Negative z values indicate viruses like SARS-CoV and MERS-CoV 356 for which symptom onset typically occurs well before infectiousness onset or peak infectivity, thus 357 making pre-symptomatic transmission insignificant or absent entirely (28, 29). In all cases, we 358 assume fixed gamma distributions for  $f_{\varepsilon}$  and  $f_r$  similar to those of the original COVID-19 variant 359 and vary z by considering different gamma distributed incubation periods  $f_I$ . Assumed means and 360 standard deviations for  $f_{\varepsilon}$ ,  $f_r$ , and  $f_I$  for the specific z values under consideration are given in 361 Table 6, and the distributions are pictured graphically in Fig. 4. Remaining model parameters are 362 taken to be equivalent to those of COVID-19 in Table 5, where we will consider a variety of  $R_0^{un}$ 363 and corresponding  $\lambda_A$  values. 364

Parameter Name		Meaning	Value	Refs
$R_0^{un}$	Uncontrolled basic re- production number	Model $R_0$ with no testing or quaran- tine control	<ul><li>3.0 (Original Variant)</li><li>6.4 (Delta Variant)</li><li>9.5 (Omicron Variant)</li></ul>	(11, 45, 46, 47, 48, 49, 50)
β	Contact rate	Average number of contacts per in- dividual per unit time	$4.0  (day)^{-1}$	Assumed
$\lambda_A$	PA transmis- sion probabil- ity	Probability of dis- ease transmission per susceptible- permanently asymptomatic contact	0.055 (Original Variant) 0.113 (Delta Variant) 0.173 (Omicron Variant)	Inferred from $R_0^{un}$
$\lambda_Y$	ES transmis- sion probabil- ity	Probability of dis- ease transmission per susceptible- eventually symp- tomatic contact	$2\lambda_A$	(13, 14, 42, 44)
	Asymptomatic fraction	Fraction of in- fections which remain mild or asymptomatic	0.75	(12, 13, 14, 15, 42, 43)
f <sub>Y</sub>	Symptomatic fraction	Fraction of infec- tions which be- come severe and symptomatic	$1-f_A$	-
N	Population size	Total number of hosts (assumed fixed)	50000	Assumed

Table 5: Model parameter definitions and numerical values used for COVID-19 variants.

Offset	z = -4.5	z = -3.0	z = -1.5	z = 0	z = 1.5	z = 3.0	z = 4.5
$\left< f_I \right> \ \sigma_I$	$1.50 \\ 1.22$	$3.00 \\ 1.91$	$4.50 \\ 2.27$	$6.00 \\ 2.83$	$7.50 \\ 2.83$	$9.00 \\ 2.83$	$10.50 \\ 2.83$
$ \begin{array}{l} \langle f_{\varepsilon} \rangle = 6.00, \ \sigma_{\varepsilon} = 2.83  \langle f_r \rangle = 17.00, \ \sigma_r = 2.06 \\ \langle f_{inf} \rangle = 11.02, \ \sigma_{inf} = 3.45  \langle f_{tot} \rangle = 17.02, \ \sigma_{tot} = 2.06 \end{array} $							

Table 6: Gamma distribution parameters for generic diseases with different offsets between mean incubation and latent periods denoted by  $z = \langle f_I \rangle - \langle f_{\varepsilon} \rangle$ . Means  $\langle \rangle$ , standard deviations  $\sigma$ , and z values are given in units of days.



Figure 4: Latent period distribution  $f_{\varepsilon}(x)$ , incubation period distributions  $f_I(x)$ , and postinfectiousness onset recovery day distribution  $f_r(x)$  as functions of the age of infection x for generic diseases with different offsets z between mean incubation and latent periods indicated in units of days.

## 365 2.3 Numerical integration and optimization

We compute the discretized dynamical equations for the system (7) using the upwind scheme for 366 non-linear partial integro-differential equations with integral boundary conditions (53), and then 367 use the midpoint method to integrate the system forward in time. We assume initial infection 368 conditions  $e_A(0,x)\Delta x = f_A$  and  $e_Y(0,x)\Delta x = f_Y$  for  $x \in [0,\Delta x]$ , where  $\Delta x = 1/6$  days is the 360 discretization length for the age of infection domain, and  $e_A(0,x) = e_A(0,y) = 0$  for  $x > \Delta x$ . The 370 system is assumed otherwise to be initially completely susceptible such that S(0) = N - 1 and 371 a(0,x) = y(0,x) = q(0,x) = R(0) = U(0) = 0 for all x. Age of infection integrals are computed 372 using the trapezoid rule where we assume a finite domain with an upper bound  $x_{max} = 80$  days 373 (the number of infected individuals who would otherwise recover after  $x_{max}$  is negligible for all 374 disease variants considered). We integrate the model equations from an initial time  $t_0 = 0$  to final 375 time  $t_f = 2$  years using a time step  $\Delta t = 1/10$  days. When implementing testing and quarantine 376 control, we find optimal allocation strategies  $\rho$  for reducing the total infection size  $S(t_0) - S(t_f)$ 377 under a variety of  $C, \eta$ , and  $\kappa$  values using the *fmincon* function in *Matlab R2021b*. 378

## 379 **3** Results

#### <sup>330</sup> 3.1 Optimal total infection size reduction and disease controllability

Figures 6 and 7 display total infection sizes under optimal resource allocation strategies as a func-381 tion of testing capacity for the different COVID variants as well as the generic disease with z and 382  $R_0^{un}$  comparable to that of delta and omicron variants (z = 1.5 days and  $R_0^{un} = 6.4$  or 9.5). Curve 383 color and dashing pattern represent different combinations of assumptions regarding symptom onset 384 (incubation symptoms or correlated symptoms) and distributions for  $f_{\varepsilon}$  and  $f_r$  (gamma or expo-385 nential) as detailed by the legend in Fig. 5. Different plots represent different disease variants and 386 different choices for  $\eta$  and  $\kappa$  values. The presented results focus on two particular cases: "random 387 testing" ( $\kappa = 1.00, \eta = 0$ ) and "realistic testing" ( $\kappa = 0.85, \eta = 0.75$ ). Random testing represents a 388 population-wide pure random sampling non-clinical testing program, while realistic testing repre-389 sents a non-clinical testing scenario more likely to be encountered in the real world, where contact 390 tracing and natural biases result in increased testing of infected individuals but where some of the 391

<sup>392</sup> population is inaccessible or resistant to testing efforts. The case of no control is represented at <sup>393</sup> zero testing capacity (C = 0). By definition, symptom onset assumptions and testing parameter <sup>394</sup> values have no influence on model outcomes at C = 0, but interestingly, we see that exponential <sup>395</sup> versus gamma distribution assumptions for  $f_{\varepsilon}$  and  $f_r$  have no meaningful impact on total infection <sup>396</sup> size at C = 0 even though model dynamics differ.

Generally, as the testing capacity C increases, Figs. 6 and 7 show that the total infection size 397 decreases when resources are distributed optimally. In particular, complete disease eradication is 398 possible at reasonably achievable testing capacities for a less infectious variant when non-clinical 399 testing can be effectively targeted at individuals who are actually infected (large  $\eta$  in Figs. 6b and 400 6d). However, if non-clinical testing does not target infected individuals (small  $\eta$  in Figs. 6a and 401 6c), or if the variant is of greater infectiousness (Fig. 7), eradication may not be achievable at 402 the reduced testing capacities available during the initial phases of a novel disease outbreak. The 403 accessibility  $\kappa$  has a smaller influence on reducing total infections compared to the concentration 404  $\eta$ , and disease eradication may possible even for smaller accessibility levels (Fig. 6d). This result 405 emphasizes the importance of implementing effective contact tracing programs for COVID-like dis-406 eases even if such programs can only reach a relatively small number of individuals. 407

Together, Figs. 6 and 7 exemplify the influences of symptom onset assumptions, period distribu-408 tion assumptions, testing parameter values, and disease variant characteristics on disease control-409 lability. By controllability, we specifically mean the amount of testing capacity required to achieve 410 a given reduction in total infection size. We consider a set 'A' of assumptions and parameters 411 to be less controllable than another set 'B' if set 'A' requires a larger testing capacity to reduce 412 total infection size to half, for example, of the uncontrolled value under optimal resource allocation 413 strategies (see Supplementary Material section S4 for alternative but equivalent measures of con-414 trollability involving the basic reproduction number). 415

Gamma versus exponential distribution assumptions for  $f_r$  have a profound effect on controllability. Comparing a dashed curve (exponential) to a solid curve (gamma) of the same color in either Fig. 6a, 6b, or 7 shows that the gamma assumption produces a large decrease in controllability relative to the exponential assumption. On the other hand, the gamma assumption for  $f_{\varepsilon}$  increases controllability relative to the exponential assumption. This is seen in Fig. 6a, 6b, or 7 by comparing a solid orange curve to a solid blue curve or a solid purple curve to a solid gold curve, and likewise

for dashed curves. The effects of incubation symptom versus correlated symptom assumptions are 422 exemplified by comparing a solid gold to solid blue curve or solid purple to solid orange curve, and 423 likewise for dashed curves. Here, incubation symptom assumptions decrease controllability relative 424 to correlated symptom assumptions. Interestingly, for a given assumption on  $f_r$ , the decrease in 425 controllability due to incubation symptoms is nullified to some extent by the increase in controlla-426 bility due to a gamma distributed  $f_{\varepsilon}$  such that solid (dashed) blue and purple curves can lie close 427 to one another bounded by solid (dashed) red and gold curves. In other words, the IPDE specific 428 assumptions for latent period length and symptom onset tend to counteract one another. However, 429 the full IPDE model (solid purple curve) generally shows a significant reduction in controllability 430 relative to the full ODE model (dashed blue curve). 431

The influences of the testing parameters  $\eta$  and  $\kappa$  on controllability are shown in Figs. 6c and 432 6d, where smaller values tend to decrease controllability. The influences of disease variant char-433 acteristics are seen by comparing Fig. 6b to the corresponding curves in all plots in Fig. 7. Here, 434 the omicron COVID variant is significantly less controllable than the delta variant, and the delta 435 variant is moderately less controllable than the original variant. These controllability reductions 436 may be caused by either increases in transmissibility or decreases in the mean latent period length 437 associated with each COVID variant, where  $R_0^{un} = 3.0, 6.4$ , and 9.5 and  $\langle f_{\varepsilon} \rangle = 5.48, 4.00$ , and 1.50 438 days for the original, delta, and omicron variants, respectively (the mean incubation-latent offsets 439 z and mean infectious period lengths are approximately equal for all variants). The independent 440 influences of transmissibility and latent period length can be deduced using the generic disease in 441 Figs. 7c and 7d. Here, the mean latent period  $\langle f_{\varepsilon} \rangle = 6.00$  days is comparable to that of the original 442 variant, and comparing Fig. 6b to Figs. 7c and 7d thus shows that increases in transmissibility 443 alone cause decreases in controllability. Likewise, comparing Fig. 7a and 7b to Fig. 7c and Fig. 7d, 444 respectively, shows that decreases in  $\langle f_{\varepsilon} \rangle$  alone cause decreases in controllability. A summary of all 445 observed controllability reducing factors is given in Table 7. 446



Figure 5: Legend for interpreting curve color and style in Figs. 6, 7, 8, 9, and 10. Different colors represent different combinations of exponential and gamma distribution assumptions for  $f_{\varepsilon}$  along with different assumptions for correlated versus incubation symptom onset as indicated by the colored table. Dashed lines indicate the exponential distribution assumption for  $f_r$  while solid lines indicate the gamma distribution assumption. The model with all IPDE elements is given by a solid purple curve while the ODE equivalent model is given by a dashed blue curve.



(a) Original Variant: Variable Distribution and Symptom Assumptions



(c) Original Variant: Gamma Distribution and Incubation Symptom Assumptions



(b) Original Variant: Variable Distribution and Symptom Assumptions



(d) Original Variant: Gamma Distribution and Incubation Symptom Assumptions

Figure 6: Total infection sizes under optimal allocation strategies as a function of testing capacity for the original COVID variant under a variety of symptom onset, period distribution, and testing parameter assumptions. The meaning of curve color and dashed versus solid curves is given in Fig. 5. Note the changes in x-axis scale for each plot.



(a) Delta Variant: Variable Distribution and Symptom Assumptions



Variable Distribution and Symptom Assumptions



(b) Omicron Variant: Variable Distribution and Symptom Assumptions



(d) Generic Disease  $R_0 = 9.3$ , z = 1.5 days. Variable Distribution and Symptom Assumptions

Figure 7: Total infection sizes under optimal allocation strategies as a function of testing capacity for the delta and omicron COVID variants, as well a generic disease similar to COVID-19, under a variety of symptom onset, period distribution, and testing parameter assumptions. The meaning of curve color and dashed versus solid curves is given in Fig. 5. The generic disease assumes  $R_0^{un}$  values equal to those of the delta and omicron COVID variants with a mean latent period  $\langle f_{\varepsilon} \rangle = 6.00$ days comparable to that of the original variant, and assumes a incubation-latent offset z = 1.5 days similar to all COVID variants. Note the changes in x-axis scale for each plot.

Controllability reducing factors for COVID-like diseases
$f_r$ gamma distribution
$f_{\varepsilon}$ exponential distribution
reduction in non-clinical concentration $\eta$
reduction in non-clinical accessibility $\kappa$
increase in overall transmissibility (i.e. $R_0^{un}$ )
reduction in mean latent period $\langle f_{\varepsilon} \rangle$
incubation symptoms

Table 7: List of controllability reducing factors observed in Figs. 6 and 7 for COVID variants and generically parameterized diseases with incubation-latent offset z = 1.5 days.

## 447 3.2 Optimal allocation strategies

Figures 8 and 9 show the optimal resource allocation strategies  $\rho$  as a function of testing capacity 448 C corresponding to the total infection size reductions in Figs. 6 and 7. Curve colors and styles are 449 interpreted analogously according to the legend in Fig. 5. The value  $\rho = 0$  represents a clinical-450 testing only strategy while  $\rho = 1$  represents a non-clinical testing only strategy, with intermediate 451 values represent mixed clinical and non-clinical testing strategies. In all cases, we find that optimal 452 strategies call for clinical testing only at low testing capacities up to some strategy threshold 453 capacity  $C^{th}$ , beyond which optimal strategies become mixed. As testing capacity increases further 454 beyond  $C^{th}$ , optimal strategies call for greater and greater shares of resources to be devoted to 455 non-clinical testing. 456

The insets in each plot (except Fig. 8d) zoom in on  $C^{th}$  values for the various distribution, 457 symptom, testing parameter, and disease parameter assumptions. Figures 8 and 9 show that all 458 of these factors except the non-clinical accessibility  $\kappa$  are important in determining  $C^{th}$ , while 459 Fig. 8d indicates that  $C^{th}$  is in fact independent of  $\kappa$ . This observation can be explained from 460 our model equations, where the total rate of flow of infected individuals to the quarantine class 461 due to non-clinical testing is given by  $\tau_N^{-1}\kappa X_N(t)$ . At the threshold  $C^{th}$ , the optimal fraction of 462 resources  $\rho$  devoted to nonclinical testing is only infinitesimally larger than zero, and Eq. (5) implies 463  $\tau_N^{-1}\kappa X_N(t) \approx \rho C N X_N(t) / \left( X_N(t) + (1-\eta)(S(t) + U(t)) \right)$  for very small  $\rho$ . We thus conclude that the 464 rate at which individuals are quarantized by optimally allocated non-clinical testing is independent 465 of  $\kappa$  at testing capacities near  $C^{th}$ , and that  $\kappa$  effectively vanishes from the model equations under 466 optimal strategies at  $C^{th}$ . 467



(a) Original Variant: Variable Distribution and Symptom Assumptions



(c) Original Variant: Gamma Distribution and Incubation Symptom Assumptions







(d) Original Variant: Gamma Distribution and Incubation Symptom Assumptions

Figure 8: Optimal resource allocation strategies for the original COVID variant corresponding to the total infection sizes in Fig. 6. The value  $\rho = 0$  corresponds to clinical-testing only strategy,  $\rho = 1$  corresponds to non-clinical testing only, with intermediate values representing mixed strategies. Insets within plots (aside from Fig. 8d) highlight strategy threshold testing capacity values  $C^{th}$  where strategies switch from clinical only to mixed. Note the changes in x-axis scale for each plot.



(a) Delta Variant: Variable Distribution and Symptom Assumptions



(c) Generic Disease  $R_0^{un} = 6.4$ , z = 1.5 days: Variable Distribution and Symptom Assumptions



(b) Omicron Variant: Variable Distribution and Symptom Assumptions



(d) Generic Disease  $R_0^{un} = 9.5$ , z = 1.5 days: Variable Distribution and Symptom Assumptions

Figure 9: Optimal resource allocation strategies for the delta and omicron COVID variants as well as comparable generic diseases with a longer mean incubation period  $\langle f_{\varepsilon} \rangle = 6.0$  days. Optimal strategies correspond to the optimal total infection sizes in Fig. 7. The value  $\rho = 0$  corresponds to clinical-testing only strategy,  $\rho = 1$  corresponds to non-clinical testing only, with intermediate values representing mixed strategies. Insets within plots highlight strategy threshold testing capacity values  $C^{th}$  where strategies switch from clinical only to mixed. Note the changes in x-axis scale for each plot.

## 468 3.3 Controllability and the role of non-clinical testing

Figures 6, 7, 8, and 9 together depict the relationship between controllability and the role of non-460 clinical testing in optimal strategies. We say that the role of non-clinical testing is increased for set 470 'A' of distribution, symptom onset, testing parameter, and disease parameter assumptions relative 471 to another set 'B' if the optimal  $\rho$  value at a given testing capacity for set 'A' is larger. Applying 472 the same comparative analyses to Figs. 8 and 9 as was done for Figs. 6 and 7 in Sec. 3.1, we 473 find that, except for the incubation symptoms assumption, all factors that reduce controllability 474 in Table 7 coincide with the factors that reduce the role of non-clinical testing. Thus there exists 475 a strong relationship between controllability influencing factors and the role of non-clinical testing 476 in optimal strategies. 477

The relationship between non-clinical testing and symptom onset assumptions is more nuanced 478 than for the other controllability reducing factors. Understanding this relationship is important 479 for disease control, as symptom onset assumptions either incorporate (incubation symptoms) or 480 disregard (correlated symptoms) the capacity for presymptomatic transmission associated with the 481 incubation-latent period offset for COVID-19. In some cases (compare gold to blue or purple to 482 orange curves in Figs. 8a and 8b), incubation symptoms decrease the role of non-clinical testing 483 relative to correlated symptoms, thus following the pattern of controllability reducing factors co-484 inciding with non-clinical testing reducing factors. In other cases (Fig. 9), incubation symptoms 485 increases the role of non-clinical testing for a large range of testing capacities above the strategy 486 thresholds  $C^{th}$  even though controllability is reduced. Of further complication, in these cases, there 487 exist smaller ranges of larger testing capacities where the role of non-clinical testing is increased by 488 the incubation symptoms assumption. 480

We utilize strategy testing capacity thresholds  $C^{th}$  to analyze the relationship between nonclinical testing and symptom onset assumptions. Specifically, in Figs. 8a and 8b, the reduced roles of non-clinical testing under the incubation symptom assumptions correspond to larger  $C^{th}$  values in comparison to the correlated symptoms assumptions. Likewise, in Fig. 9, the enhanced roles of non-clinical testing over large ranges of testing capacities correspond to smaller  $C^{th}$  for incubation symptoms in comparison to correlated symptoms. Thus, increases and decreases in  $C^{th}$  due to symptom onset assumptions are simple indicators of decreases and increases, respectively, in the

<sup>497</sup> roles of non-clinical testing. To further simplify our analysis, we restrict our attention to the most <sup>498</sup> realistic model assumptions using gamma distributions for  $f_{\varepsilon}$  and  $f_r$  to compare incubation symp-<sup>499</sup> toms (solid purple curves) to correlated symptoms (solid orange curves).

Numerically calculating  $C^{th}$  values for a spectrum of  $\eta$  values, we plot the results as curves in 500 the  $(C, \eta)$  plane, where different curves represent different variant and symptom onset assumptions 501 (Fig. 10). For a given variant, if the correlated symptom curve (orange) falls to the left of the 502 incubation symptom (purple) curve at a given  $\eta$ , then  $C^{th}$  is larger for incubation symptoms, thus 503 implying that incubation symptoms reduce the role of non-clinical testing. Conversely, if the cor-504 related symptom curve falls to the right of the incubation symptoms curve, incubation symptoms 505 enhance the role of non-clinical testing. Further, for each variant, there exists a threshold concen-506 tration  $\eta^{th}$  (indicated by black circles in Fig. 10), above which the role of non-clinical testing is 507 always enhanced, and below which it is always reduced, where threshold values decrease as variant 508 strength increases. Thus, whether or not the presence of presymptomatic transmission warrants 509 allocation of additional resources to non-clinical testing than would otherwise be optimal depends 510 on both variant strength and the precision to which non-clinical tests can locate infected individ-511 uals: variants with greater infectiousness require less precision to justify additional resources for 512 non-clinical testing. 513

Figure 10 is of additional value as a practical result for disease management officials when 514 determining whether or not complicated resource allocation decisions need be considered. To see 515 this, suppose that the available testing capacity C and an estimate for the concentration  $\eta$  of a 516 non-clinical testing program are known. Then, if the corresponding  $(C, \eta)$  value falls to the left of 517 or below a variant curve in Fig. 10, the optimal strategy for that variant is clinical testing only, and 518 officials need not consider difficult choices in allocating resources. Otherwise, if the  $(C, \eta)$  value 519 falls to the right of or above a variant curve, the optimal strategy is mixed clinical and non-clinical 520 testing, and officials know that critical decisions must be made to ensure that resources are properly 521 allocated. 522



Figure 10: Strategy threshold testing capacities at various concentration levels  $\eta$  for the different COVID variants. Curves represent  $(C, \eta)$  values where the strategy threshold capacity  $C^{th}$  occurs, assuming either incubation symptoms (purple) or correlated symptoms (orange) with gamma distributed  $f_r$  and  $f_{\varepsilon}$ . At  $(C, \eta)$  points above or to the right of a given curve, optimal strategies are mixed clinical and non-clinical for that variant and symptom assumption. At points below or to the left, optimal strategies are clinical only. Circles indicate points where  $C^{th}$  is equivalent for both symptom assumptions. At  $\eta$  values above a circle, incubation symptoms increases the role of non-clinical testing in optimal strategies for the corresponding variant. At  $\eta$  values below a circle, incubation symptoms reduce the role of non-clinical testing.

## <sup>523</sup> 3.4 Variable incubation-latent offsets

In Fig. 11, we plot optimal total infection sizes and corresponding optimal resource allocation 524 strategies for the generic disease with  $R_0^{un} = 3.0$  under a variety of incubation-latent offsets z. 525 Here, we consider only gamma distributions for  $f_r$  and  $f_{\varepsilon}$ , and we consider both incubation and 526 correlated symptom assumptions (the offset z is irrelevant under correlated symptoms). The offset 527 z is found to have a strong influence on controllability (Figs. 11a and 11b); as z increases from neg-528 ative to positive values, controllability decreases significantly. Thus, diseases for which symptom 529 onset typically occurs before peak infectiousness are more easily controlled with symptom-based 530 interventions compared to diseases for which symptom onset typically occurs after infectiousness 531 onset (i.e. presymptomatic transmission). Further, relative to the correlated symptoms assump-532 tion, incubation symptoms are more controllable for z < 0 and less controllable for z > 0 (Figs. 11a) 533 and 11b). This finding agrees with the notion that diseases for which symptoms precede signif-534 icant infectiousness are easier to control; if a model disregards the offset between symptom and 535 infectiousness onset, it will underestimate controllability for diseases with z < 0 and overestimate 536 controllability for diseases with z > 0. Thus, Table 1 should be modified to state that incubation 537 symptoms are a controllability reducing factor only for diseases with z > 0, while correlated symp-538 toms are a controllability reducing factor for z < 0. This expanded list of controllability reducing 539 factors is given in Table 8. For the case z = 0, controllability under incubation symptoms is close to 540 (but not exactly equal to) controllability under correlated symptoms (Figs. 11a and 11b). Appar-541 ently, when symptom and infectiousness onset occur together only on average rather than always 542 together, controllability is very slightly reduced. 543

As a function of testing capacity, optimal strategies for all z behave qualitatively similar to 544 those of the COVID-19 variants; optimal strategies are clinical-only at low testing capacities and 545 become mixed clinical and non-clinical beyond a threshold capacity  $C^{th}$  (Figs. 11c and 11d). As 546 with the COVID-19 variants, the relationships between symptom onset assumptions, controllabil-547 ity, and optimal allocation strategies are complicated for the generic disease. For random testing 548 (Fig. 11c), the role of non-clinical testing decreases (as measured by increases in  $C^{th}$ ) as z increases 549 in the interval [-4.5, 1.5], thus following the trend of controllability reducing factors coinciding with 550 non-clinical testing reducing factors. However, the role of non-clinical testing increases for z = 4.5551

days relative to z = 1.5 days even though controllability decreases. For realistic testing (Fig. 11d), the role of non-clinical testing decreases progressively as z increases in the interval [-4.5, 0], after which it progressively increases as z increases in [0, 4.5]. Of further complication, for larger  $R_0^{un}$ values (see Supplementary Material Figs. S10 and S11), the role of non-clinical testing can increase progressively as z increases despite the progressive decrease in controllability.

The role of non-clinical testing for incubation symptoms relative to that of correlated symp-557 toms displays distinct behavior for z < 0 and  $z \ge 0$ . Specifically, for z = -1.5 days (green curve 558 in Figs. 11c and 11d), the role of non-clinical testing is enhanced relative to correlated symptoms 559 at  $\eta = 0$ , but is reduced at  $\eta = 0.85$ . This behavior is counterintuitive; one would expect that 560 if non-clinical testing is effective enough at low  $\eta$  to have an enhanced role in optimal strategies, 561 then it would also have an enhanced role at larger  $\eta$ , as increasing  $\eta$  would increase its efficacy 562 further. This is indeed the case for the COVID-19 variants that have a positive z approximately 563 equal to 1.50 days (Fig. 10). For these variants, the role of non-clinical testing becomes enhanced 564 relative to correlated symptoms at some threshold concentration  $\eta^{th}$ , and then remains enhanced 565 for all  $\eta > \eta^{th}$ . Figure 12 presents the analog to Fig. 10 for the generic disease for  $R_0^{un} = 3.0$ 566 (see Supplementary Material Figs.  $R_0^{un} = 6.4$  and  $R_0^{un} = 9.5$ ). Here, we numerically calculate 567 the strategy threshold capacities  $C^{th}$  for a spectrum of  $\eta$  values for each z offset and the corre-568 lated symptoms assumptions, and then plot the results as curves in the  $(C, \eta)$  plane. For each z 569 curve, there is a threshold concentration  $\eta^{th}$  where a crossing with the correlated symptoms curve 570 occurs.  $z \ge 0$  curves are to the right of the correlated symptoms curve for  $\eta < \eta^{th}$  (indicating 571 diminished non-clinical testing roles) and to the left for  $\eta > \eta^{th}$  (indicating enhanced non-clinical 572 testing roles). However, z < 0 curves are to the left of the correlated symptoms curve for  $\eta < \eta^{th}$ 573 (indicating enhanced non-clinical testing roles) and to the right for  $\eta > \eta^{th}$  (indicating diminished 574 non-clinical testing roles). We thus find major qualitative differences between z > 0 diseases (i.e. 575 those with presymptomatic transmission) and z < 0 diseases (i.e those with symptom onset before 576 infectiousness) in regards to the influence of realistic incubation and latent periods on optimal re-577 source allocation strategies relative to simpler models. 578

From Figs. 10 and 12 (as well as the corresponding Figs. S12 and S13 in the Supplementary Material), it is clear that threshold concentrations  $\eta^{th}$  depend on both the incubation-latent offset z and the overall transmissibility as measured by  $R_0^{un}$ , and may also depend on the mean latent

period length. To visualize these influences, we find the thresholds  $\eta^{th}$  numerically for the  $z \leq 0$ 582 diseases as well as the COVID-19 variants, assuming a spectrum of  $R_0^{un}$  values for each model by 583 changing the overall transmissibility. The results are plotted in Fig. 13 as curves in the  $(R_0^{un}, \eta)$ 584 plane, where each curve represents  $\eta^{th}$  values for a different set of gamma distributed latent and 585 incubation periods taken from Tables 2, 3, 4, and 6, assuming gamma distributions for  $f_r$ . If a 586 disease management official is designing a testing resource allocation strategy to control a disease 587 for which they know the basic reproduction number and an estimate for their testing program's 588  $\eta$  reproduction, they can locate the corresponding point in Fig. 13. If their point falls above the 589 relevant incubation/latent period assumption curve, then due to presymptomatic transmission, op-590 timal strategies will call for an increase in non-clinical testing resources relative to a comparable 591 simpler disease for which infectiousness and symptoms always coincide. If their point falls below the 592 relevant incubation/latent period assumption curve, optimal strategies will call for a reduction in 593 non-clinical testing relative to a comparable simpler disease despite the presence of presymptomatic 594 transmission. Generally, smaller  $R_0^{un}$  values require greater  $\eta$  to justify allocating extra resources 595 to non-clinical testing, thus corroborating our previous observation that diseases with greater in-596 fectiousness require less precise non-clinical testing programs (i.e. smaller  $\eta$ ) to justify allocating 597 additional resources to non-clinical testing due to presymptomatic transmission. We see further 598 that larger z diseases and diseases with shorter latent periods (compare the omicron curve to the 599 z = 1.50 curve) likewise require less precision to justify increasing resources to non-clinical testing. 600 In other words, the factors of larger  $R_0^{un}$ , larger z, and smaller latent period expand the parameter 601 space for which non-clinical testing is enhanced in optimal strategies due to presymptomatic trans-602 mission. Note that as  $R_0^{un}$  falls below 2.0, enhanced non-clinical testing is never justified. Thus, 603 diseases with sufficiently low infectiousness do not warrant additional non-clinical testing resources, 604 even if presymptomatic transmission may be significant. 605



(a) Generic Disease  $R_0^{un} = 3.0$ : Gamma Distribution Assumptions and Variable Incubation-Latent Offsets



(c) Generic Disease  $R_0^{un} = 3.0$ : Gamma Distribution Assumptions and Variable Incubation-Latent Offsets



(b) Generic Disease  $R_0^{un} = 3.0$ : Gamma Distribution Assumptions and Variable Incubation-Latent Offsets



(d) Generic Disease  $R_0^{un} = 3.0$ : Gamma Distribution Assumptions and Variable Incubation-Latent Offsets

Figure 11: Optimal total infection sizes and corresponding optimal resource allocation strategies for the generic disease with  $R_0^{un} = 3.0$ , assuming gamma distributions for  $f_{\varepsilon}$  and  $f_r$ . Curve colors represent different offsets  $z = \langle f_I \rangle - \langle f_{\varepsilon} \rangle$  between mean incubation and latent periods as indicated by the legend in Fig. 11a (measured in units of days). Black dashed curves represent the correlated symptoms assumption where z values are irrelevant. Insets in Figs. 11c and 11d zoom in on strategy threshold testing capacities  $C^{th}$  where optimal strategies switch from clinical only to mixed clinical and non-clinical.

Controllability reducing factors
$f_r$ gamma distribution
$f_{\varepsilon}$ exponential distribution
reduction in non-clinical concentration $\eta$
reduction in non-clinical accessibility $\kappa$
increase in overall transmissibility (i.e. $R_0^{un}$ )
reduction in mean latent period $\langle f_{\varepsilon} \rangle$
incubation symptoms when $z > 0$
correlated symptoms when $z < 0$

Table 8: Expanded list of controllability reducing factors for both z > 0 and z < 0 diseases as observed in Figs. 6, 7, and 11.



Figure 12: Strategy threshold testing capacities at various concentration levels  $\eta$  for the generic disease with  $R_0^{un} = 3.0$ . Curves represent  $(C, \eta)$  values where the strategy threshold capacity  $C^{th}$  occurs, assuming either incubation symptoms (colored curves) or correlated symptoms (black dashed curve) with gamma distributed  $f_r$  and  $f_{\varepsilon}$ . Colors represents different off sets z between the mean incubation and mean latent period, with values in the legend given in units of days. At  $(C, \eta)$  points above or to the right of a given curve, optimal strategies are mixed clinical and non-clinical for that z value or symptom assumption. At points below or to the left, optimal strategies are clinical only. The  $\eta$  value for which a colored curve crosses the black curve represents a threshold  $\eta^{th}$  for which the role of non-clinical testing switches between enhanced and diminished compared to the correlated symptoms assumption.



Figure 13: Curves depicting threshold concentrations  $\eta^{th}$  as a function of the uncontrolled basic reproduction number for gamma distributed latent and incubation period associated with the COVID-19 variants and our generic diseases, where  $f_r$  is assumed to be gamma distributed. Each curve represents a different latent/incubation period set that has a particular incubation-latent offset z denoted in the legend in units of days. The legend specifies the COVID variants along with their z offsets, and the generic disease indicated by only their z offsets. The actual  $R_0^{un}$  values for the COVID variants are indicated by makers on the plot. Points above a given curve represent the parameter space over which presymptomatic transmission justifies increasing resources to nonclinical testing for a disease with the corresponding latent and incubation periods. For points below a curve, presymptomatic transmission does not justify increasing non-clinical testing resources in optimal strategies.

# 606 4 Discussion

## 607 4.1 Curbing epidemics under resource limitations

The results of our work build a robust mathematical justification for the optimality of the test-608 ing strategies adopted by real-world disease management planners during the early phases of the 600 COVID-19 pandemic. Namely, when testing resources are in short supply, they should be reserved 610 for the most symptomatic and critically ill patients (6, 7, 8). Although these policies may have 611 been adopted to prevent mortality, we have found that they are also good policies for suppressing 612 an epidemic. More generally, our work shows that such policies are optimal for a broad range 613 of disease characteristics and non-clinical testing program characteristics. Diseases with longer or 614 shorter latent periods, stronger or weaker transmissibility, presymptomatic transmission or symp-615 tom onset before infectiousness or correlated symptom-infectiousness onset, and exponential or 616 gamma period distributions all call for qualitatively similar policies as a function of testing ca-617 pacity; optimal protocols call for clinical-only testing at testing capacities below a threshold  $C^{th}$ , 618 and call for mixed clinical and non-clinical strategies at greater testing capacities. Interestingly, 619 in a previous work (18) where we analyzed optimally reducing the epidemic peak height (rather 620 than total infection size) using the reduced and simplified ODE counterpart of our model here, we 621 observed the same threshold behavior separating testing capacity regions between optimal clinical-622 only and mixed strategies. Thus, the threshold behavior appears to be a general feature of optimal 623 allocation strategies under limited testing resources. 624

Figures 6, 7, and 11 depicting optimal total infection size for "realistic" and "random" non-625 clinical testing programs illuminate the feasibility or infeasibility of curbing a novel disease outbreak 626 with a testing and quarantine program. Random testing  $(\eta = 0)$  is unlikely to be successful at the 627 low testing capacities expected at the initial stages of a novel disease outbreak as production of 628 newly developed tests falls well behind demand, even if the entire population is accessible and 629 amenable to the limited number of tests available ( $\kappa = 1$ ). However, significant disease suppression 630 is possible at larger concentrations  $\eta$  even if the overall accessibility  $\kappa$  is small. This result stresses 631 the importance of early implementation of effective contact tracing and public outreach programs 632 encouraging individuals with suspected or probable recent transmission to seek testing, even if 633 significant portions of the population are not open or accessible to such efforts. Importantly, this 634

conclusion holds for the spectrum of model assumptions and disease characteristics analyzed in this
 paper.

## <sup>637</sup> 4.2 Influence of model assumptions on controllability

Throughout this work, we have identified a number of disease characteristics and model assumptions 638 that influence predictions of controllability. Model assumptions regarding latent period, incubation 630 period, and recovery day distributions as well as incubation-latent offsets are critically important, 640 as we have found that the exponential distribution and correlated symptom assumptions in the 641 equivalent ODE model can severely overestimate controllability relative to the full IPDE model 642 for the COVID-19 variants. The gamma distribution assumptions for  $f_{\varepsilon}$ ,  $f_I$ , and  $f_r$  used in the 643 full IPDE model are supported by epidemiological data and are far more realistic than ODE as-644 sumptions, so the reduced controllability exhibited by our model is a closer reflection of reality. 645 Our model's ability to decouple symptom onset from disease compartments plays a key role in its 646 capacity to simultaneously incorporate realistic latent and incubation period distributions. 647

A major contributing factor to reduced controllability in the full IPDE model is the gamma 648 period distribution for  $f_r$ . This observation accords with previous models with identification + isola-649 tion/quarantine controls, where it was observed that an exponentially distributed infectious period 650 can significantly overestimate controllability relative to a gamma distribution (27). In essence, 651 quarantining is more effective under the exponential assumption due to its ability to significantly 652 reduce the infectious period length of individuals in the long tail of the distribution (see Fig. 3). 653 Likewise, under the exponential assumption, significantly larger numbers individuals recover nat-654 urally within the first few days of infectiousness onset in comparison to the gamma assumption. 655 so delays in testing due to low capacity are irrelevant in these cases and are thus less detrimental 656 to controllability. Conversely, for the latent period distribution, a gamma distribution assumption 657 increases controllability relative to the exponential assumption (although to a lesser degree than 658 that with which a gamma  $f_r$  reduces controllability) for reasons analogous to those of infectious 659 period. Namely, under the exponential assumption, much larger numbers of individuals rapidly 660 transition from exposed to infectious in comparison to the gamma distribution, so there is less time 661 to locate and remove new infections before they begin generating new transmissions, and delays in 662 identifying and quarantining infections due to supply limitations are thus more detrimental. On a 663

more basic level, although gamma distributions for  $f_{\varepsilon}$  and  $f_r$  have no noticeable effect on total infection size under no control, they flatten/delay and sharpen/accelerate the uncontrolled epidemic peak, respectively, as compared to exponential distributions (see the Supplementary Material section S3). Intuitively, a disease that peaks earlier and to a greater degree on its on volition will be more difficult to control.

Symptom onset assumptions based on the age-of-infection can reduce or increase controllability 669 depending on the incubation-latent offset z, as controllability generally decreases as z increases. 670 Under correlated symptoms, active spreaders in the ES class always show symptoms and are thus 671 always targeted with efficacious clinical testing. Under incubation symptoms, however, positive z672 values imply presymptomatic transmissions, meaning that some of the active spreaders can only 673 be targeted with non-clinical testing which is subject to delays due to resources being wasted on 674 uninfected individuals. These delays become more detrimental as the presymptomatic transmission 675 window becomes larger, so controllability tends to decrease as z increases. For negative z, however, 676 some individuals become symptomatic while still in the exposed class, so efficacious clinical testing 677 can be used to remove infected individuals with minimal delay before they can begin generating 678 new transmissions. This is impossible under correlated symptoms or positive z values. The oppor-679 tunity for clinical testing to remove preinfectious individuals increases as z grows in the negative 680 direction, and controllability consequently increases. Notably, the increase in controllability can be 681 significant for a negative z disease compared to a positive z disease. This observation may explain 682 why the 2003 SARS outbreak (negative z disease) was far easier to control than the COVID-19 683 pandemic (positive z disease) (54). 684

The remaining controllability reducing factors are straightforwardly explained. Namely, a more 685 transmissible disease (i.e. one with a larger  $R_0^{un}$ ) is inherently more difficult to control than a less 686 transmissible disease, and the larger number of secondary infections generated by an individual can 687 be detrimental to control when limited resources force delays in testing and quarantine. Likewise, 688 shorter latent periods leave less time to locate infected individuals before they begin generating 689 transmissions, so testing and quarantine delays become more costly. These factors together help 690 explain why the omicron variant has been particularly challenging to control (49, 55). The large 691  $R_0^{un}$  value is an oft emphasized contributing factor, but the short latent period relative to other 692 variants can be just as important. Explicitly, comparing the generic disease (mean latent period 6 693

<sup>694</sup> days) to the omicron variant (mean latent period 1.5 days) in Fig. 7 shows that omicron is roughly <sup>695</sup> half as controllable despite both diseases having the same  $R_0^{un}$ .

## <sup>696</sup> 4.3 Controllability, symptom onset, and the role of non-clinical testing

Our results across all model assumptions demonstrate a consistent clear relationship between non-697 clinical testing and controllability reducing factors unrelated to symptom onset assumptions: factors 698 that reduce controllability also reduce the role of non-clinical testing in optimal strategies. We hy-699 pothesize that this relationship arises because wasted or inefficiently used resources are of greater 700 detriment in a less controllable system. That is, when a disease is considered less controllable, fail-701 ure to utilize a quantity of testing capacity to identify and isolate infected individuals will result in 702 a greater number of additional infections in comparison to a more controllable disease. With non-703 clinical testing, the beneficial impact of identifying removing non-symptomatic infected individuals 704 is counterbalanced by the negative impact of potentially wasting tests on uninfected individuals, 705 and the negative impact becomes more prominent as the disease becomes less controllable. Thus, 706 optimal strategies place more emphasis on clinical testing which is guaranteed to be utilized to iden-707 tify and isolate an infected individual. However, for sufficiently large testing capacity, resources are 708 plentiful enough such that wasting a test on an uninfected individual does not significantly delay or 709 inhibit identification of infected individuals, so the role of non-clinical testing can be prominent in 710 a less controllable disease, although still slightly diminished in comparison to a more controllable 711 disease. Thus, the observed relationship between the role of non-clinical testing and controllability 712 is closely tied to the resource limitation aspects of model. 713

In contrast to factors unrelated to symptom onset, the relationship symptom onset assumptions 714 and non-clinical testing is unclear. One one hand, one might expect that for a negative z disease like 715 COVID-19, realistically modeling the incubation-latent offset will increase the role of of non-clinical 716 testing in comparison to a model making the simpler correlated symptom assumption due to the 717 ability of non-clinical testing to capture presymptomatic spreaders. On the other hand, since the 718 latent incubation offset decreases controllability for a negative z disease, one might expect the role 719 of non-clinical testing to be diminished due to the reasoning given in the preceding paragraph. We 720 found that neither of these hypotheses are generally correct for guiding optimal strategies based 721 on the results of simple ODE models. Instead, we found that age-of-infection modeling, and in 722

particular, the details of the temporal offset between the incubation and latent periods, was critical 723 to understanding disease progression, controllability, and optimal strategies for resource allocation. 724 Our results show that optimal policies for resource allocation depend on a complicated (often 725 non-intuitive) interplay between incubation-latent offset, disease strength, and other characteris-726 tics like latent period length (Figs. 11, 12, 13 and the corresponding Figs. S10, S11, S12, S13 in 727 the Supplementary Material). This is a critical observation because real-world public policies and 728 attitudes towards a novel diseases are typically based on what has been successful for previous 729 diseases combined with basic intuition for the broad differences between the novel disease and pre-730 vious diseases. For example, 2003 SARS has no presymptomatic transmission while COVID-19 has 731 significant presymptomatic transmission, so one might intuitively expect that a successful strat-732 egy for controlling 2003 SARS should be adapted for COVID-19 by allocating more resources to 733 non-clinical testing to capture presymptomatic spreaders, but this is not at all the case accord-734 ing to our results. Our work shows that this intuition-based approach to public policy can fail. 735 and thus highlights the importance of mathematical modeling in helping to guide disease man-736 agement. In particular, it is important to establish modeling frameworks where different diseases 737 can be examined comparatively under the same lens to more closely mimic the way diseases are 738 compared in the real world. Utilizing the age-of-infection to decouple symptom status from specific 739 model compartments is the crucial element for allowing such comparisons in our model. Future 740 models may build upon these ideas to incorporate not only the age-of-infection, but also the age-741 of-infectiousness to model additional realistic features like partial correlations between incubation. 742 latent, and infectious period lengths as well as time-varying infectivity levels dependent on the time 743 since infectiousness or symptom onset. 744

# 745 Acknowledgments

This work was funded by the Center of Advanced Systems Understanding (CASUS) which is financed by Germanys Federal Ministry of Education and Research (BMBF) and by the Saxon Ministry for Science, Culture and Tourism (SMWK) with tax funds on the basis of the budget approved by the Saxon State Parliament.

# 750 **References**

- [1] World Health Organization. WHO Director-General's opening remarks at the media
   briefing on COVID-19 11 March 2020, 2020. [cited 2022 October 24]. Available
   from: https://www.who.int/director-general/speeches/detail/who-director-general-s-opening remarks-at-the-media-briefing-on-covid-19—11-march-2020.
- [2] World Health Organization. WHO COVID-19 Dashboard, 2020. [cited 2022 October 24].
   Available from: https://covid19.who.int/.
- [3] Antoine Mandel and Vipin Veetil. The economic cost of COVID lLockdowns: An outof-eEquilibrium analysis. *Econ Disaster Clim Chang*, 4:431–451, 2020. doi: 10.1007/
  s41885-020-00066-z.
- [4] Adam Rose. COVID-19 economic impacts in perspective: A comparison to recent U.S. disasters. Int J Disaster Risk Reduct, 60:102317, June 2021. doi: 10.1016/j.ijdrr.2021.102317.
- [5] Eva Clark, Elizabeth Y Chiao, and E Susan Amirian. Why contact tracing efforts have failed
  to curb coronavirus disease 2019 (COVID-19) transmission in much of the United States. *Clin Infect Dis*, 72:e415-e419, 2021. doi: 10.1093/cid/ciaa1155.
- [6] E. Susan Amirian. Prioritizing COVID-19 test utilization during supply shortages in the late
   phase pandemic. J Public Health Policy, 43:320–324, 2022. doi: 10.1057/s41271-022-00348-8.
- [7] Centers for Disease Control and Prevention. Investigating a COVID-19 case, 2022. [cited
   2022 October 24]. Available from: https://www.cdc.gov/coronavirus/2019-ncov/php/contact-tracing/contact-tracing-plan/investigating-covid-19-case.html.
- [8] World Health Organization. Public health surveillance for COVID-19: Interim guidance, 2022.
  [cited 2022 October 24]. Available from: https://www.who.int/publications/i/item/WHO2019-nCoV-SurveillanceGuidance-2022.2.
- [9] William V. Padula. Why only test symptomatic patients? Consider random screening for COVID-19. Appl Health Econ Health Policy, 18:333–334, 2020. doi: 10.1007/
  s40258-020-00579-4.

776	[10] Hualei Xin, Yu Li, Peng Wu, Zhili Li, Eric H Y Lau, Ying Qin, Liping Wang, Benjamin J
777	Cowling, Tim K Tsang, and Zhongjie Li. Estimating the latent period of coronavirus disease
778	2019 (COVID-19). Clin Infect Dis, 74:1678–1681, 2022. doi: 10.1093/cid/ciab746.

[11] Min Kang, Hualei Xin, Jun Yuan, Sheikh Taslim Ali, Zimian Liang, Jiayi Zhang, Ting
Hu, Eric HY Lau, Yingtao Zhang, Meng Zhang, Benjamin J Cowling, Yan Li, and Peng
Wu. Transmission dynamics and epidemiological characteristics of SARS-CoV-2 Delta variant infections in Guangdong, China, May to June 2021. *Eurosurveillance*, 27, 2022. doi:
10.2807/1560-7917.ES.2022.27.10.2100815.

[12] Nathan W. Furukawa, John T. Brooks, and Jeremy Sobel. Evidence supporting transmission
 of severe acute respiratory syndrome coronavirus 2 while presymptomatic or asymptomatic.
 *Emerg Infect Dis*, 26:e201595, 2020. doi: 10.3201/eid2607.201595.

- [13] Kieran A. Walsh, Karen Jordan, Barbara Clyne, Daniela Rohde, Linda Drummond, Paula
  Byrne, Susan Ahern, Paul G. Carty, Kirsty K. O'Brien, Eamon O'Murchu, Michelle O'Neill,
  Susan M. Smith, Mirn Ryan, and Patricia Harrington. SARS-CoV-2 detection, viral load and
  infectivity over the course of an infection. J Infect, 81:357–371, 2020. doi: 10.1016/j.jinf.2020.
  06.067.
- [14] Arabella Widders, Alex Broom, and Jennifer Broom. SARS-CoV-2: The viral shedding vs
   infectivity dilemma. *Infect Dis Health*, 25:210–215, 2020. doi: 10.1016/j.idh.2020.05.002.
- [15] Qiuyue Ma, Jue Liu, Qiao Liu, Liangyu Kang, Runqing Liu, Wenzhan Jing, Yu Wu, and Min
   Liu. Global percentage of asymptomatic SARS-CoV-2 infections among the tested population
   and individuals with confirmed COVID-19 diagnosis: A systematic review and meta-analysis.
   JAMA Netw Open, 4:e2137257, 2021. doi: 10.1001/jamanetworkopen.2021.37257.
- [16] Amin Yousefpour, Hadi Jahanshahi, and Stelios Bekiros. Optimal policies for control of the
   novel coronavirus disease (COVID-19) outbreak. *Chaos Solitons Fractals*, 136:109883, 2020.
   doi: 10.1016/j.chaos.2020.109883.
- <sup>801</sup> [17] Lautaro Vassallo, Ignacio A. Perez, Lucila G. Alvarez-Zuzek, Julin Amaya, Marcos F. Torres,

- COVID-19 transmission in Argentina: Exploration of the alternating quarantine and massive 803 testing strategies. Math Biosci, 346:108664, 2022. doi: 10.1016/j.mbs.2021.108664. 804
- [18] Justin M. Calabrese and Jeffery Demers. How optimal allocation of limited testing capacity 805 changes epidemic dynamics. J Theor Biol, 538:111017, 2022. doi: 10.1016/j.jtbi.2022.1110173. 806
- [19] Alberto Olivares and Ernesto Staffetti. Optimal control-based vaccination and testing 807 strategies for COVID-19. Comput Methods Programs Biomede, 211:106411, 2021. doi: 808 10.1016/j.cmpb.2021.106411. 809
- [20] Steffen E. Eikenberry, Marina Mancuso, Enahoro Iboi, Tin Phan, Keenan Eikenberry, Yang 810 Kuang, Eric Kostelich, and Abba B. Gumel. To mask or not to mask: Modeling the potential 811 for face mask use by the general public to curtail the COVID-19 pandemic. Infect Dis Model. 812 5:293-308, 2020. doi: 10.1016/j.idm.2020.04.001. 813
- [21] Kristina P. Vatcheva, Josef Sifuentes, Tamer Oraby, Jose Campo Maldonado, Timothy Huber, 814 and Mara Cristina Villalobos. Social distancing and testing as optimal strategies against the 815 spread of COVID-19 in the Rio Grande Valley of Texas. Infect Dis Model, 6:729–742, 2021. 816 doi: 10.1016/j.idm.2021.04.004. 817
- [22] Calistus N. Ngonghala, Enahoro A. Iboi, and Abba B. Gumel. Could masks curtail the post-818 lockdown resurgence of COVID-19 in the US? Mathl Biosci, 329:108452, 2020. doi: 10.1016/ 819 j.mbs.2020.108452. 820
- [23] Colin J. Worby and Hsiao-Han Chang. Face mask use in the general population and optimal 821 resource allocation during the COVID-19 pandemic. Nat Commun, 11:4049, 2020. doi: 10. 822 1038/s41467-020-17922-x. 823
- [24] Sarah F. Poole, Jessica Gronsbell, Dale Winter, Stefanie Nickels, Roie Levy, Bin Fu, Maximilien 824 Burg, Sohrab Saeb, Matthew D. Edwards, Michael K. Behr, Vignesh Kumaresan, Alexander R. 825 Macalalad, Sneh Shah, Michelle Prevost, Nigel Snoad, Michael P. Brenner, Lance J. Myers, 826 Paul Varghese, Robert M. Califf, Vindell Washington, Vivian S. Lee, and Menachem Fromer. 827 A holistic approach for suppression of COVID-19 spread in workplaces and universities. PLoS 828 One, 16:e0254798, 2021. doi: 10.1371/journal.pone.0254798.

829

49

[25] Joshua Kiddy K. Asamoah, Zhen Jin, Gui-Quan Sun, Baba Seidu, Ernest Yankson, Afeez
 Abidemi, F.T. Oduro, Stephen E. Moore, and Eric Okyere. Sensitivity assessment and op timal economic evaluation of a new COVID-19 compartmental epidemic model with control
 interventions. *Chaos Soliton Fractal*, 146:110885, 2021. doi: 10.1016/j.chaos.2021.110885.

[26] Paul J. Hurtado and Adam S. Kirosingh. Generalizations of the Linear Chain Trick: incorpo-

rating more flexible dwell time distributions into mean field ODE models. J Math Biol, 79(5):

1831–1883, 2019. doi: 10.1007/s00285-019-01412-w.

[27] Helen J Wearing, Pejman Rohani, and Matt J Keeling. Appropriate models for the management of infectious diseases. *PLoS Med*, 2:e174, 2005. doi: 10.1371/journal.pmed.0020174.

[28] Zhonglan Wu, David Harrich, Zhongyang Li, Dongsheng Hu, and Dongsheng Li. The unique
features of SARSCoV2 transmission: Comparison with SARSCoV, MERSCoV and 2009 H1N1
pandemic influenza virus. *Rev Med Virol*, 31:e2171, 2021. doi: 10.1002/rmv.2171.

<sup>842</sup> [29] Guang Zeng, Shu-Yun Xie, Qin Li, and Jian-Ming Ou. Infectivity of severe acute respiratory
<sup>843</sup> syndrome during its incubation period. *Biomed Environ Sci*, 22:502–510, 2009. doi: 10.1016/
<sup>844</sup> S0895-3988(10)60008-6.

[30] Andrew William Byrne, David McEvoy, Aine B Collins, Kevin Hunt, Miriam Casey, Ann Barber, Francis Butler, John Griffin, Elizabeth A Lane, Conor McAloon, Kirsty O'Brien, Patrick
Wall, Kieran A Walsh, and Simon J More. Inferred duration of infectious period of SARS-CoV2: Rapid scoping review and analysis of available evidence for asymptomatic and symptomatic
COVID-19 cases. *BMJ Open*, 10:e039856, 2020. doi: 10.1136/bmjopen-2020-039856.

[31] Muge Cevik, Matthew Tate, Ollie Lloyd, Alberto Enrico Maraolo, Jenna Schafers, and Antonia
Ho. SARS-CoV-2, SARS-CoV, and MERS-CoV viral load dynamics, duration of viral shedding, and infectiousness: A systematic review and meta-analysis. *Lancet Microbe*, 2:e13–e22,
2021. doi: 10.1016/S2666-5247(20)30172-5.

[32] Jantien A Backer, Don Klinkenberg, and Jacco Wallinga. Incubation period of 2019 novel
 coronavirus (2019-nCoV) infections among travellers from Wuhan, China, 2028 January 2020.
 *Eurosurveillance*, 25, 2020. doi: 10.2807/1560-7917.ES.2020.25.5.2000062.

<sup>857</sup> [33] Stephen A. Lauer, Kyra H. Grantz, Qifang Bi, Forrest K. Jones, Qulu Zheng, Hannah R.
<sup>858</sup> Meredith, Andrew S. Azman, Nicholas G. Reich, and Justin Lessler. The incubation period
<sup>859</sup> of coronavirus disease 2019 (COVID-19) from publicly reported confirmed cases: Estimation
<sup>860</sup> and application. Ann Intern Med, 172:577–582, 2020. doi: 10.7326/M20-0504.

[34] Qun Li, Xuhua Guan, Peng Wu, Xiaoye Wang, Lei Zhou, Yeqing Tong, Ruiqi Ren, Kathy S.M. 861 Leung, Eric H.Y. Lau, Jessica Y. Wong, Xuesen Xing, Nijuan Xiang, Yang Wu, Chao Li, 862 Qi Chen, Dan Li, Tian Liu, Jing Zhao, Man Liu, Wenxiao Tu, Chuding Chen, Lianmei Jin, 863 Rui Yang, Qi Wang, Suhua Zhou, Rui Wang, Hui Liu, Yinbo Luo, Yuan Liu, Ge Shao, Huan Li, 864 Zhongfa Tao, Yang Yang, Zhiqiang Deng, Boxi Liu, Zhitao Ma, Yanping Zhang, Guoqing Shi, 865 Tommy T.Y. Lam, Joseph T. Wu, George F. Gao, Benjamin J. Cowling, Bo Yang, Gabriel M. 866 Leung, and Zijian Feng. Early transmission dynamics in Wuhan, China, of novel coronavirus-867 infected pneumonia. N Engl J Med, 382:1199–1207, 2020. doi: 10.1056/NEJMoa2001316. 868

[35] Conor McAloon, ine Collins, Kevin Hunt, Ann Barber, Andrew W Byrne, Francis Butler,
Miriam Casey, John Griffin, Elizabeth Lane, David McEvoy, Patrick Wall, Martin Green,
Luke O'Grady, and Simon J More. Incubation period of COVID-19: A rapid systematic
review and meta-analysis of observational research. *BMJ Open*, 10:e039652, 2020. doi: 10.
1136/bmjopen-2020-039652.

[36] Balram Rai, Anandi Shukla, and Laxmi Kant Dwivedi. Incubation period for COVID-19: A
systematic review and meta-analysis. J Public Health, 2021. doi: 10.1007/s10389-021-01478-1.

<sup>876</sup> [37] Hualei Xin, Jessica Y Wong, Caitriona Murphy, Amy Yeung, Sheikh Taslim Ali, Peng Wu,
<sup>877</sup> and Benjamin J Cowling. The incubation period distribution of coronavirus disease 2019: A
<sup>878</sup> systematic review and meta-analysis. *Clin Infect Dis*, 73:2344–2352, December 2021. doi:
<sup>879</sup> 10.1093/cid/ciab501.

[38] Hideo Tanaka, Tsuyoshi Ogata, Toshiyuki Shibata, Hitomi Nagai, Yuki Takahashi, Masaru
Kinoshita, Keisuke Matsubayashi, Sanae Hattori, and Chie Taniguchi. Shorter incubation
period among COVID-19 cases with the BA.1 Omicron variant. Int J Environ Res Public
Health, 19:6330, 2022. doi: 10.3390/ijerph19106330.

51

- [39] Lauren Jansen. Investigation of a SARS-CoV-2 B.1.1.529 (omicron) variant cluster Nebraska,
   NovemberDecember 2021. MMWR. Morbidity and Mortality Weekly Report, 70, 2021. doi:
   10.15585/mmwr.mm705152e3.
- [40] Javier Del guila Meja, Reinhard Wallmann, Jorge Calvo-Montes, Jess Rodrguez-Lozano,
   Trinidad Valle-Madrazo, and Adrian Aginagalde-Llorente. Secondary attack rate, transmission
   and incubation periods, and serial interval of SARS-CoV-2 Omicron variant, Spain. *Emerg Infect Dis*, 28:1224–1228, 2022. doi: 10.3201/eid2806.220158.
- [41] Mina Park, Colleen Pawliuk, Tribesty Nguyen, Amanda Griffitt, Linda Dix-Cooper, Nadia
  Fourik, and Martin Dawes. Determining the communicable period of SARS-CoV-2: A rapid
  review of the literature, March to September 2020. *Euro Surveil*, 26, 2021. doi: 10.2807/
  1560-7917.ES.2021.26.14.2001506.
- <sup>895</sup> [42] Yang Liu, Li-Meng Yan, Lagen Wan, Tian-Xin Xiang, Aiping Le, Jia-Ming Liu, Malik Peiris,
  <sup>896</sup> Leo L M Poon, and Wei Zhang. Viral dynamics in mild and severe cases of COVID-19. Lancet
  <sup>897</sup> Infect Dis, 20:656–657, 2020. ISSN 14733099. doi: 10.1016/S1473-3099(20)30232-2.
- [43] A. Maisa, G. Spaccaferri, L. Fournier, J. Schaeffer, J. Deniau, P. Rolland, B. Coignard, A. An-898 drieu, O. Broustal, S. Chene, S. Chent, E. Fougre, G. Gbaguidi, M. Hamidouche, A. Lamy, 899 Q. Mano, B. Mastrovito, A. Mercier, G. Modenesi, G. Picard, J. Prudhomme, F. Rapilly, 900 A. Riondel, M. Rivire, B. Villegas Ramirez, A. Zhu-Soubise, M. Zurbaran, A. Amzert, L. An-901 dreoletti, A. Bal, R. Beaurepere, S. Behillil, L. Belec, C. Bernard, L. Bocket, L. Bouri, 902 T. Bourlet, C. Bressollette-Bodin, S. Brichler, C. Brugerolles, S. Cado, V. Calvez, N. Capron, 903 S. Castelain, J. Castro-Alvarez, M.-L. Chaix, C. Charpentier, D. Che, C. Chillou, P. Colson, 904 P. Coudene, A. Crinquette, A. De Rougemont, H. Delagrverie, C. Delamare, T. Denecker-905 Berardino, D. Descamps, M. Desroches, G. Destras, G. Dos Santos, A. Ducancelle, S. Ducreux, 906 T. Duret, V. Enouf, S. Fafi-Kremer, C. Felici, S. Fourati, P.-E. Fournier, C. Gaudy, H. Ger-907 main, V. Giordanengo, O. Gorge, S. Haim-Boukobza, C. Henquell, A. Holstein, L. Houhamdi, 908 J. Izopet, V. Jacomo, A. Jacques, M.-C. Jaffar-Bandjee, M. Jimenez, L. Josset, S. Kemeny, 909 M.-E. Lafon, A. Le Bars, G. Le Corguille, Q. Lepiller, A. Levasseur, N. Leveque, B. Lina, 910 C. Madelaine, C. Malabat, S. Marque-Juillet, T. Martin-Dunavit, P. Mavingui, A. Merens, 911

I. Messak, L. Morand-Joubert, X. Naudot, P. Neybecker, J.-M. Pawlotsky, L. Pilorge, J.-C.
Plantier, C. Poggi, M. Pretet, C. Ragot, H. Raoul, S. Rogez, A.-M. Roque-Afonso, B. Roquebert, D. Rousset, F. Rozenberg, C. Sagot, S. Sahnoune, D. Salgado, O. Sand, C. Saudemont,
E. Schvoerer, E. Simon-Loriere, R. Stephan, J. Sudour, V. Thibault, E. Tuaillon, A. Vabret,
E. Vallee, S. Van Der Werf, J. Van Helden, L. Verdurme, A. Vignola, D. Wilkinson, and
Yazdanpanah. First cases of Omicron in France are exhibiting mild symptoms, November
2021January 2022. Infect Dis Now, 52:160–164, 2022. doi: 10.1016/j.idnow.2022.02.003.

- [44] Andrew A Sayampanathan, Cheryl S Heng, Phua Hwee Pin, Junxiong Pang, Teoh Yee Leong,
  and Vernon J Lee. Infectivity of asymptomatic versus symptomatic COVID-19. Lancet, 397:
  93–94, 2021. doi: 10.1016/S0140-6736(20)32651-9.
- [45] Maimuna S Majumder and Kenneth D Mandl. Early in the epidemic: impact of preprints on
  global discourse about COVID-19 transmissibility. *Lancet Glob Health*, 8:e627–e630, 2020. doi:
  10.1016/S2214-109X(20)30113-3.
- [46] Ral Patricio Fernndez-Naranjo, Eduardo Vsconez-Gonzlez, Katherine Simbaa-Rivera, Lenin
  Gmez-Barreno, Juan S. Izquierdo-Condoy, Domnica Cevallos-Robalino, and Esteban OrtizPrado. Statistical data driven approach of COVID-19 in Ecuador: R0 and Rt estimation via
  new method. *Infect Dis Model*, 6:232–243, 2021. doi: 10.1016/j.idm.2020.12.012.
- [47] Cheng-Jun Yu, Zi-Xiao Wang, Yue Xu, Ming-Xia Hu, Kai Chen, and Gang Qin. Assessment
  of basic reproductive number for COVID-19 at global level: A meta-analysis. *Medicine*, 100:
  e25837, 2021. doi: 10.1097/MD.00000000025837.
- [48] Ying Liu and Joacim Rockly. The reproductive number of the Delta variant of SARS-CoV-2
  is far higher compared to the ancestral SARS-CoV-2 virus. J Travel Med, 28:taab124, 2021.
  doi: 10.1093/jtm/taab124.
- [49] Talha Khan Burki. Omicron variant and booster COVID-19 vaccines. Lancet Respir Med, 10:
   e17, 2022. doi: 10.1016/S2213-2600(21)00559-2.
- 937 [50] Ying Liu and Joacim Rockly. The effective reproductive number of the Omicron variant

53

of SARS-CoV-2 is several times relative to Delta. J Travel Med, 29:taac037, 2022. doi:
10.1093/jtm/taac037.

<sup>940</sup> [51] Yoshiaki Gu, Nobuhiro Komiya, Hajime Kamiya, Yoshinori Yasui, Kiyosu Taniguchi, and
<sup>941</sup> Nobuhiko Okabe. Pandemic (H1N1) 2009 transmission during presymptomatic phase, Japan.
<sup>942</sup> Emerg Infect Dis, 17:1737–1739, 2011. doi: 10.3201/eid1709.101411.

- 943 [52] F. T. M. Freitas, A. P. S. Cabral, E. N. C. Barros, M. J. O. Burigo, R. D. Prochnow, L. A.
- Silva, M. A. Widdowson, and J. Sobel. Pre-symptomatic transmission of pandemic influenza
- H1N1 2009: investigation of a family cluster, Brazil. *Epidemiol Infect*, 141:763–766, 2013. doi:
  10.1017/S0950268812001501.
- <sup>947</sup> [53] J.C. Lopez-Marcos. An upwind scheme for a nonlinear hyperbolic integro-differential equation with integral boundary condition. *Comput Math Appl*, 22:15–28, 1991. doi: 10.1016/
  <sup>949</sup> 0898-1221(91)90030-8.
- <sup>950</sup> [54] Monica Gandhi, Deborah S. Yokoe, and Diane V. Havlir. Asymptomatic transmission, the
  <sup>951</sup> Achilles heel of current strategies to control Covid-19. N Engl J Med, 382:2158–2160, 2020.
  <sup>952</sup> doi: 10.1056/NEJMe2009758.
- <sup>953</sup> [55] Luke Taylor. Covid-19: Hong Kong reports worlds highest death rate as zero covid strategy
  <sup>954</sup> fails. *BMJ*, page o707, 2022. doi: 10.1136/bmj.o707.